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CHAPTER I 
 
INTRODUCTION 
 
Part I. Pulmonary Hypertension 
 
Definition of Pulmonary Hypertension 
 Pulmonary hypertension (PH) is most simply defined as an increase in mean pulmonary 
artery pressure (mPAP) greater than or equal to 25 mm Hg at rest using right heart 
catheterization.  Resting mPAPs in heritable pulmonary arterial hypertension (HPAH) patients 
with BMPR2 mutations, can be as high as 61 mm Hg compared to 56 mm Hg in pulmonary 
arterial hypertension (PAH) patients without BMPR2 mutation [1,2].  This is in contrast to a 
normal mPAP, which is defined as 14 +/- 3.3 mm Hg at rest with the upper most mPAP that is 
still considered clinically normal at 20.6 mm Hg [3,4].  Interestingly, patients with mPAPs that 
are between 21-24 mm Hg remain undefined clinically [3].   
 Previously, a mPAP of greater than 30 mm Hg during exercise has been used to help 
diagnose patients with PH.  However, it has been increasingly shown that clinically normal 
patients can also reach mPAPs of greater than 30 mm Hg during exercise.  Because of this, 
meausurement of mPAP during exercise is no longer as widely accepted as a clinical assessment 
of PH [3-5].          
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Table 1.WHO Current Clinical Classification of Pulmonary Hypertension Adapted from [6] 
Group 1.  Pulmonary arterial hypertension 
1.1 Idiopathic pulmonary arterial hypertension 
1.2 Heritable pulmonary arterial hypertension 
1.2.1 BMPR2 
1.2.2 ALK1, Endoglin 
1.2.3 Unknown  
1.3 Drug and toxin-induced pulmonary arterial hypertension 
1.4 Associated with 
1.4.1 Connective tissue diseases 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1.4.6 Chronic hemolytic anemia 
1.5 Persistent Pulmonary Hypertension of the newborn 
1’ Pulmonary veno-occulusive disease and/or pulmonary capillary hemangiomatosis  
Group 2.  Pulmonary Hypertension as a result of left heart diseases 
           2.1 Systolic dysfunction 
           2.2 Diastolic dysfunction 
           2.3 Valvular disease 
Group 3.  Pulmonary Hypertension associated with lung diseases and/or hypoxia 
           3.1 Chronic obstructive pulmonary disease 
           3.2 Interstitial lung disease 
           3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
           3.4 Sleep-disordered breathing 
           3.5 Aveolar hypoventilation disorders 
           3.6 Chronic exposure to high altitude 
           3.7 Developmental abnormalities 
Group 4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
Group 5. Pulmonary hypertension with unclear multifactorial mechanisms 
           5.1 Hematologic disorders 
           5.2 Systemic disorders 
           5.3 Metabolic disorders 
           5.4 Others: tumor obstruction, chronic renal failure 
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 More recently, measurements of pulmonary vascular resistance (PVR), cardiac output 
(CO), and pulmonary wedge pressure (PWP) have been used in combination as a way to 
hemodynamically assess patients with PH.  PWP in particular has been used to classify patients 
with pre-capillary PH (PWP less than or equal to 15 mm Hg) or post-capillary PH (PWP greater 
than 15 mm Hg).  This provides a way to distinguish between clinical groups of patients; those 
patients with pre-capillary PH fall within clinical groups 1, 3, 4, and 5.  Patients with post-
capillary PH fall within clinical group 2 (PH due to left heart disease) [3,6].   
Classification of Pulmonary Hypertension 
 The first classification system for PH was developed in 1973 and had only two groups; 
patients could be categorized with prim-ary or secondary PH [3,7].  The current World Health 
Organization (WHO) classification system, developed in 2008, incorporates current research and 
clinical assessment.  Patients can be categorized into one of five groups, and further classified 
into subgroups based on hemodynamics, similar disease pathogenesis and characteristics, and 
response to therapeutics (Table 1)[3,6]. 
 Group 1 of the classification system is comprised of patients that develop pulmonary 
arterial hypertension (PAH) and include multiple causalities of PAH ranging from sporadic cases 
to disease-associated cases.  It is important to note that PAH is distinct from other forms of PH, 
and is a group in the classification system for PH.  It consists of idiopathic and heritable 
pulmonary arterial hypertension, drug-induced pulmonary hypertension (most notably the diet 
drug fenfluramine) [8,9], connective tissue disease-associated hypertension [10-13], pulmonary 
hypertension of newborns [14], and pulmonary hypertension associated with pulmonary veno-
occlusive disease [15] [3,6].   
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Of interest, idiopathic pulmonary arterial hypertension (IPAH), which is defined as 
sporadic pulmonary hypertension occurring in patients with no family history or identified risk 
factors, occurs at an incidence of 2-3 new cases per million people a year [3,6,16].  The heritable 
pulmonary arterial hypertension (HPAH) subgroup includes germline mutations in genes 
BMPR2, ACVRL1, CAV1, or ENDOGLIN in patients with or without a family history [6,17-19].  
Interestingly, germline mutations in BMPR2 occur in 10-40% of all new incidences of 
pulmonary arterial hypertension [17,20].  Additionally, the HPAH group includes patients with a 
family history but no identified germline mutation.  Together, IPAH and HPAH account for 
roughly 1500 new cases a year in the USA [21].  In contrast, the remaining PAH patients account 
for 3000 new cases a year [6,21]. 
 Group 2 of the PH classification system are made up of patients with left heart disease 
(systolic, diastolic dysfunction or valvular disease).  This group develops PH due to increased 
left atrial pressure.  This increase in pressure in the atrium leads to a backward transmission of 
pressure causing a gradual increase in pulmonary arterial pressure, increase in vascular tone, and 
remodeling [22].  Patients have a PWP of greater than 15 mm Hg, making this form of PH post-
capillary in contrast to every other group.  This group makes up the majority of cases of PH, 
however treatment options are limited, and currently the efficacy of PAH treatments on this 
population of PH patients is unknown [3,6]. 
 Group 3 develop PH due to lung diseases and/or hypoxia.  The most dominant cause of 
PH in this group is due to COPD but its prevalence is largely unknown [23,24].  Patients 
classified in Group 4 develop chronic thromboembolic PH.  On average, 4% of patients with an 
acute pulmonary embolism develop PH [25].  Group 5 consists of patients that develop PH from 
unclear or multifactorial mechanisms.  This includes patients that develop PH after hematologic 
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disorders, systemic disorders, metabolic disorders, thyroid disorders, and other causes including 
chronic renal failure [26-30].          
Pathobiology of Pulmonary Hypertension 
 Patients with PH have progressive obliteration of small pulmonary arteries, abnormal 
vasoreactivity, right ventricle hypertrophy and eventual right heart failure (cor pulmonale) 
[3,31].  PH is characterized by remodeling of the distal pulmonary arteries, intimal thickening, 
proliferation of vascular smooth muscle cells and apoptosis-resistance pulmonary artery 
endothelial cells, increased fibrosis, and in the most severe cases the formation of plexiform 
lesions which are a unique feature to severe PH and are complex lesions containing capillary-like 
channels [32-34].      
Incidence and treatment 
 There are 2.4-7.6 new cases of HPAH (the focus of this dissertation) per million people 
annually [35].  Although rare, current available therapies are largely ineffective, resulting in a 5 
year survival rate of just 60% in patients with PAH and just 48% in patients with HPAH [36].  
The most common treatment for PH, including patients with PAH, is currently prostacyclin  
(epoprostenol), a vasodilator.  PH patients receiving prostacylins have an 84% 2 year survival 
rate [37]. Calcium channel-blockers are also used.  Calcium channel-blockers inhibit calcium 
influx into smooth muscle cells leading to vasodilation of the pulmonary vasculature.  Calcium 
channel blockers have been shown to improve 5 year survival to 97%.  However, only a subset 
of PH patients responds to vasodilator therapy, and in PAH just 10% of IPAH patients and even 
fewer HPAH patients are responsive [2,38].  Endothelin receptor antagonists, which function by 
inhibiting the vasoconstrictive activity of Endothelin-1 [39], and Phosphodiesterase-5 inhibitors, 
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which inhibit the degradation of cGMP (activated in response to vasodilator Nitric Oxide) by 
Phosphodiesterase-5 leading to vasodilation of the pulmonary vasculature [40], are 
also currently used with 91% and 72% 2 year survival rates respectively [41].  Although current 
therapies target vasodilatory pathways to improve quality of life, they do not reverse vascular 
remodeling and do not help maintain normal hemodynamics in the long term.         
Heritable Pulmonary Arterial Hypertension and BMPR2 mutations 
 Mutations in the BMPR2 receptor have been identified in 70% of HPAH patients, 
including 10% of patients who have had no prior family history of PAH [20,42,43].  There is 
also evidence of BMPR2 dysregulation as a contributor to other forms of PH [44,45].  Patients 
with a mutation in BMPR2 clinically present symptoms on average 10 years earlier than PAH 
patients without mutation, have more severe hemodynamics, mortality at an earlier age [1,17], 
and are less likely to respond to vasodilator therapy [1,2].  To date, over 200 different BMPR2 
mutations have been identified in HPAH patients [31,45-47], and the exact role of BMPR2 
mutation in disease pathogenesis is an area of active investigation.  This dissertation investigates 
the role of BMPR2 mutation type and its effect on experimental PH.   
 
Part II. Signaling and function of the BMPR2 receptor 
 
The Bone Morphogenetic Protein (BMP) family 
 BMPs make up the largest subset of the TGF- superfamily of proteins, which in addition 
to BMPs include Growth differentiation factors (GDFs), activins, and nodal (reviewed in [48-
7 
 
51]).  They were first identified by, and subsequently named for inducing the ectopic bone 
formation [52].  Members of the TGF- family are grouped due to similarities in structure, 
receptor binding, and signaling function.  Members of this superfamily control a diverse range of 
developmental and cellular processes including embryonic patterning, formation of the 
mesoderm, development of the kidney, lung, heart, amnion, eye, lung, and in embryonic and 
adult stem cell self-renewal and differentiation pathways, to name a few [53-56].  Currently, 
there are 15 identified mammalian BMP ligands that bind and signal through two distinct types 
of receptors.  Type I receptors include Activin-like kinase (Alk) 1,2,3,and 6.  Type II receptors 
include BMPR2, Activin like kinase receptor 2 (ActR2A) and ActR2B [50,55].     
BMP receptor structure and signaling complex formation 
 Type I and Type II BMP receptors are made up of an extracellular domain containing the 
ligand binding domain, a single pass transmembrane domain, and an intracellular kinase domain.  
Both types of receptors are serine/threonine kinases, however the Type II receptors are 
constitutively active while the Type I receptors are inhibited due to the interaction of repressor 
protein FKBP12, which prevents phosphorylation of the G/S box, a glycine/serine rich region 
unique to Type I receptors [48,57,58].  Of note, the BMPR2 receptor has an additional 530 
amino acid cytoplasmic tail that is unique among other receptor family members [59].   
To initiate signaling responses, BMP ligand binds preferentially to Type I receptors, 
which in turn recruits Type II receptors to form a hetero-tetrameric complex [60,61].  BMPs 5-8 
are exceptions to this, these ligands preferentially bind to the Type II receptor and subsequently 
recruit the Type I receptor to the complex [49].  Once in proximity to the Type I receptor, the 
Type II receptor is able to initiate a conformational change in the Type I receptor leading to the 
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dissociation of the repressor protein FKBP12 from the G/S box, and then phosphorylate the Type 
I receptor and initiate downstream signaling pathways.  Signaling through the Smad pathway has 
been identified as the canonical BMP-mediated pathway.  Once activated by phosphorylation of 
the c-terminus by the Type I receptor, regulatory Smads, Smad 1, Smad 5, and Smad 8, with the 
aid of co-Smad 4, translocate to the nucleus where they regulate transcription of target genes.  
Inhibitory Smads 6 and Smad 7 regulate the amount and duration of signal of the regulatory 
Smads.   
Non-canonical signaling responses ERK1/2, p38MAPK, JNK, PI3K, and Rho kinase 
have also been shown to be activated in response to BMP stimulation [62].  Type I and Type II 
receptors have distinct binding affinities for different BMP ligands, however receptors and 
ligands are promiscuous and are able to activate downstream signaling responses after 
stimulation from different combinations of ligand and receptor (Table 2)[51]. 
 Complexes between Type I and particularly Type II receptors are able to form in the 
absence of BMP ligand, however stimulation with BMP results in a 2-3 fold increase in complex 
formation.  There is increasing evidence that the preformed complexes preferentially activate 
canonical signaling pathways while the BMP-mediated receptor complexes preferentially 
stimulate noncanonical pathways [60,61]. 
 Although the heteromeric complex formation between Type I and Type II receptors is 
necessary and sufficient to induce downstream canonical and non-canonical signaling pathways, 
a number of co-receptors have been identified to further modulate BMP signaling responses.  
These co-receptors, including Endoglin, TGFR3, RGMa, DRAGON, and Bambi, have been  
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Table 2.  Known BMP ligand and BMP receptor interactions, adapted from [51] 
Ligand Type I Receptor Type II Receptor Reference 
Bmp2 Alk3, Alk6 Bmpr2, Actr2, Actr2B [63,64]  
Bmp4 Alk3, Alk6 Bmpr2, Actr2, Actr2B [63-65] 
Bmp6 Alk2, Alk3, Alk6 Bmpr2, Actr2, Actr2B [66] 
Bmp7 Alk2, Alk3, Alk6 Bmpr2, Actr2 [65,67] 
Bmp9 Alk1, Alk2 Bmpr2, Actr2, Actr2B [68,69] 
Bmp10 Alk1, Alk3, Alk6 Bmpr2 [69] 
Gdf5 Alk3, Alk6 Bmpr2 [70,71] 
Gdf6 Alk3, Alk6 Bmpr2, Actr2B [71] 
Gdf9 Alk3, Alk6 Bmpr2, Actr2 [72] 
Gdf9B Alk6 Bmpr2 [73] 
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shown to regulate BMP receptor-ligand interactions providing another level of regulation to the 
BMP-signaling response [48,50].           
BMP signaling and vascular disease 
 In addition to the identification of BMPR2 mutants, mutations in other BMP signaling 
pathway proteins including Endoglin, ALK1, SMAD4 and 8 have been identified in HPAH 
patients without BMPR2 mutations [51,74,75].  Additionally, these proteins have been 
implicated in other vascular diseases.  Over 80% of patients with Hereditary Hemorrhagic 
Telangiectasia (HTT), characterized by arteriovenous malformations, have mutations in ALK1 or 
ENG.  A small percentage of HHT patients may have mutations in SMAD4.  Interestingly, HHT 
patients may develop PAH in addition to HTT [51,76,77].     
BMPR2 signaling responses in HPAH 
BMP signaling in the pulmonary vasculature is cell-type and ligand dependent [2,51,78].  
Expression of BMP receptors and ligands is tightly regulated by the pulmonary vasculature 
(Table 3) [51,79].  However, the pulmonary vasculature is made up of a heterogenic population 
of cells, even amongst cells of the same type-for example endothelial cells, therefore, it is not 
uncommon to observe opposing signaling responses in the same cell type in distinct regions of 
the pulmonary vasculature [80,81]. This is likely due to the different developmental origins of 
the endothelium making up the macro-and micro pulmonary vasculature.  The macro-vascular 
endothelium (greater than 100 m) is developed through angiogenesis of the pulmonary truncus, 
whereas the endothelium comprising the pulmonary micro-vasculature is developed via 
vasculogenesis of blood islands [82,83].  The different developmental origin of the macro- and 
micro-pulmonary vascular endothelium causes distinct expression and phenotypic differences  
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 Table 3.  Expression of BMP signaling components in the human pulmonary vasculature 
modified from RT-PCR data [84] 
 
 
 
 
 
 
 
 
 
 
BMP family member Human pulmonary artery 
endothelial cells 
Human vascular smooth 
muscle cells 
BMP Type I receptors ALK1, ALK2, ALK5, ALK6 ALK2, ALK3, ALK5, ALK6 
BMP Type II receptors ACTR2, ACTR2B, BMPR2 ACTR2, ACTR2B, BMPR2 
BMP ligands BMP2 BMP2 
BMP co-receptor ENDOGLIN, BETAGLYCAN ENDOGLIN, BETAGLYCAN 
SMAD SMAD1, SMAD2, SMAD3, 
SMAD4, SMAD5 
SMAD1, SMAD2, SMAD3, 
SMAD4, SMAD5 
TGF- TR-II, TGF-1 TR-II, TGF-1 
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between regions of the pulmonary vasculature.  The heterogeneity of the endothelium 
comprising the pulmonary vasculature leads to different integration of signaling pathways, 
including the BMP pathway, in response to stimuli.  For example, BMPs are pro-apoptotic in 
smooth muscle cells from the main artery, but are pro-proliferative in smooth muscle cells from 
more distal arteries [85-87].  In general, studies have shown BMP2, BMP4, BMP6, and BMP7 
are largely expressed by the pulmonary vasculature and play a variety of cell-type dependent 
functions including vascular homeostasis, regulation of vasoreactivity, and endothelial cell 
function [80,81,88].   
BMPR2 is predominately expressed in the pulmonary endothelium, but to a lesser extent 
is also expressed in vascular smooth muscle cells [44,89].  BMP2 and BMP4 stimulate 
phosphorylation of eNOS in pulmonary artery endothelial cells (PAECs) which lead to 
endothelial cell migration via BMPR2 and PKA dependent mechanisms [80,90].  Endothelial cell 
migration is necessary for the repair of pulmonary arteries in response to vascular injury.  Lack 
of endothelial cell migration and initiation of repair pathways is thought to contribute to HPAH 
pathogenesis by exposing SMCs to growth factors and inflammatory proteins in the circulation, 
which could in turn contribute to the vascular remodeling observed in disease [91].  In fact in 
PAECs with BMPR2 mutations, there is decreased phosphorylation of eNOS, providing a 
possible mechanism for vascular remodeling [90].  Additionally, BMP4 stimulates reactive 
oxygen species production in endothelial cells, and in some endothelial cell types, initiate 
apoptosis.  BMPR2 expression in PAECs also induces the formation of a complex between 
PPAR and -catenin [92].  This protein complex upregulates the expression of apelin, which is 
required to modulate normal responses to vascular injury, resulting in another vascular injury 
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repair pathway that is impaired with the loss of expression and function of BMPR2 in HPAH 
[92].       
BMPs are expressed in, and secreted by, endothelial cells. This in turn influences smooth 
muscle cell (SMC) function in the pulmonary vasculature.  BMP2, 4, and 7 inhibit vascular SMC 
proliferation [44,81,85,93,94].  Additionally, BMP4 decreases the expression of anti-apoptotic 
protein Bcl-2, leading to increased apoptotic sensitivity in SMCs.  In SMCs isolated from HPAH 
patients with mutations in BMPR2, BMP2 and BMP7 stimulation increased SMC proliferation 
[95].  SMCs isolated from patients with IPAH (no mutation in BMPR2) had decreased 
Smad1/5/8 activation and an increase in p38 activation[95].  Proliferation in these cells was 
inhibited by stimulation with BMP4.  Overall levels of BMPR2 expression were reduced in these 
cells isolated from IPAH and HPAH patients, but unlike the IPAH SMCs, SMCs isolated from 
HPAH patients did not have reduced proliferative responses due to BMP4 stimulation [95]. 
Increasingly, in vivo models have been used to determine the role of BMP signaling in 
vascular disease.  Heterozygous Bmpr2 null mice, Bmpr2+/-, have slightly elevated pulmonary 
vascular resistance and increased susceptibility to PH with the addition of chronic hypoxia + 
serotonin or inflammatory stress [96-98].  These mice do not display increased vascular 
remodeling in response to hypoxia [96].  Mice carrying an hpyomorphic allele, Bmpr2Ex2/+, 
have increased susceptibility to chronic hypoxia PH [99].  Bmpr2+/- and Bmpr2Ex2/+ mice have 
increased pulmonary vasoconstriction [98,99], but the Bmpr2Ex2/+ mice also have defects in 
endothelial cell-dependent and independent vasodilation [99]. The Bmpr2Ex2/+ mice also have 
reduced eNOS expression, suggesting defects in eNOS pathway are responsible for the 
endothelial cell-dependent vasodilatory defects [99].  Mice with an endothelial cell-specific 
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deletion of Bmpr2 spontaneously develop PH in a subset of mice [100].  Interestingly, mice 
overexpressing a dominant negative Bmpr2 mutation in SMCs also develop spontaneous PH 
[101].  These studies show that Bmpr2 signaling influences both SMCs and ECs to help regulate 
vascular homeostasis.        
Part III. BMPR2 mutation type and experimental PH 
 
BMPR2 mutation type and disease 
 50-80% of HPAH patients have a germline mutation in BMPR2 [20,42,43].  Patients with 
a BMPR2 mutation are less likely to react to vasodilator therapy, more likely to present clinical 
symptoms at a younger age, and have a shorter time to death or lung transplantation compared to 
IPAH patients without a BMPR2 mutation [1,2,17].  Despite this, disease severity among patients 
with a BMPR2 mutation is not uniform.  Differences of penetrance, age of onset, and age of 
death vary widely between mutation carriers [102].  This is likely due in part to the large number 
of identified BMPR2 mutations, over 200, and spread of mutations throughout the BMPR2 gene 
[45-47,103].  It is likely the location of the BMPR2 mutation affects the resulting protein 
production differently and leads to different phenotypic responses.  60% of BMPR2 mutations 
are identified as nonsense, or frameshift mutations [45].  This type of mutation is degraded by 
the nonsense-mediated mRNA decay pathway (NMD) [104].  NMD is an RNA surveillance 
pathway that recognizes mutated RNA that would otherwise be translated into a potentially 
detrimental mutant protein (reviewed in [105]).  BMPR2 mutations that are positive for the NMD 
pathway (NMD+) are degraded and result in a happloinsufficient phenotype [104].  Conversely, 
40% of identified BMPR2 mutations are missense mutations, and are unlikely to be recognized 
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by the NMD machinery.  The result from this type of mutation (NMD-) is likely the production 
of a mutant BMPR2 protein.  Though not without controversy [106], clinical data indicates that 
HPAH patients with NMD- BMPR2 mutations have more severe disease, a shorter time to lung 
transplant, and earlier age of diagnosis compared to patients with an NMD+ BMPR2 mutation 
[104].  In Chapter II of this dissertation we utilize two different mouse models with germline 
Bmpr2 mutations, one NMD+ and one NMD- and three experimental models of PH to determine 
if we could recapitulate the clinical data, that NMD- Bmpr2 mutants have more severe PH, in 
vivo.  We also attempt to characterize the impact of Bmpr2 mutation type on the progression and 
severity of experimental PH.  We demonstrate that NMD- mutants have a higher right ventricular 
systolic pressure (RVSP), have an increase in vascular obstructive lesions, and impaired 
phospho-eNOS signaling.     
 To further characterize the NMD- Bmpr2 mutant, we wanted to determine if the predicted 
NMD- mutant protein product was endogenously expressed.  To do this we isolated pulmonary 
endothelial cells (PECs) and used lymphocytes from an HPAH family expressing the same 
NMD- mutation in which EXON2 is deleted.  Once we were able to establish that the mutant 
Bmpr2Ex protein was expressed, we next wanted to determine if the mutant protein was able to 
reach the cell surface.  We found that the NMD- product was mis-trafficked and retained in the 
endoplasmic reticulum and that PECs had impaird phospho-Smad1/5/8 signaling function and 
reduced expression of the Smad1/5/8 target gene, Id1.  We show that trafficking to the cell 
surface and signaling function can be restored in the NMD- Bmpr2 mutant with the addition of 
chemical chaperones 4-PBA and TUDCA, providing possible therapeutic application for certain 
types of mutations.  
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 HPAH-patient cells are difficult to obtain, requiring a lung biopsy, are often of end-stage 
disease, and have limited capacity to propagate.  In chapter 4 we establish several induced 
Pluripotent Stem Cell lines (iPSCs) from HPAH patient fibroblasts with known NMD+ and 
NMD- BMPR2 mutations with the aim to further examine the link between NMD BMPR2 
mutation status and disease severity using HPAH patient-derived iPS cells that have been 
differentiated into endothelial cells.  Additionally, we plan to expand our in vitro findings to 
other NMD- BMPR2 mutations.  We report preliminary findings with an endothelial 
differentiation protocol in control IPS cells.  The creation of these lines would provide a source 
of patient-derived cells that could be utilized to dissect the role of BMPR2 mutation type and 
signaling function in endothelial and smooth muscle cells.  The studies presented in chapter 4 are 
preliminary, and require further validation and characterization.  
 Collectively, these studies describe how Bmpr2 mutations contribute to HPAH.  We 
determine if different types of BMPR2 mutation result in different phenotypic outcomes.  We 
utilize in vivo and in vitro methods using mouse models and patient samples to try to 
characterize the function of NMD- and NMD+ mutations on the severity of experimental PH.  
We further evaluate the expression, localization, and signaling capacity of a Bmpr2 NMD- 
mutation predicted to express a mutant protein in vivo.  Together, our data show that NMD- and 
NMD+ Bmpr2 mutations alter different signaling pathways and lead to experimental PH likely 
through different mechanisms.      
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CHAPTER II 
 
EFFECT OF NMD STATUS IN BMPR2 HETERZYGOUS MUTANTS IN CHRONIC 
HYPOXIA, SEROTONIN, AND SU5416 MODELS OF PH 
 
Introduction 
HPAH patients with mutations in BMPR2 have more severe disease as characterized by 
decreased responsiveness to vasodilator drugs [1,2], younger age at diagnosis and worse 
hemodynamics [1,17], and shorter time to death or lung transplant [17] compared to PAH 
patients.  Recently, two clinical groups published conflicting results from two different patient 
cohorts linking BMPR2 mutation NMD status and severity of disease.  The first group found 
patients with BMPR2 NMD- mutations (making up 40% of identified BMPR2 mutations) had an 
increase in disease severity [104].  HPAH patients with NMD- BMPR2 mutations had an even 
earlier age of onset compared to BMPR2 NMD+ mutants and shorter time to lung transplant 
[104].     Conversely, the second group, using a different patient cohort, showed that there were 
no significant differences in disease severity between BMPR2 mutation types.  
Based on this controversy, we set out to characterize biologically how BMPR2 mutation 
status might affect disease severity.  To do this we evaluated the effects of three different models 
of experimental PH (chronic hypoxia, serotonin + hypoxia, and VEGFR2 inhibitor SU5416 + 
hypoxia) on a mouse model of an NMD+ mutation (Bmpr2+/-) and a mouse model of an NMD- 
mutation (Bmpr2Ex2/+) to determine in vitro if we could reproduce the clinical data. 
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Studies from our laboratory have shown that mice carrying a heterozygous mutation at 
the Bmpr2 locus, Bmpr2Ex2/+, which is indistinguishable from the NMD- HPAH Family 108 
mutation, described in chapter 3, develop more severe hypoxic PH [99]. This is in contrast to 
reported findings showing mice carrying a heterozygous null Bmpr2+/- mutation, similar to an 
NMD+ HPAH Family 20 mutation, which are only more slightly susceptible to hypoxic PH [96].  
However, until recently direct assessment of the role of different Bmpr2 mutation type in 
experimental PH was not possible, mainly owing to the fact that the Bmpr2 mutant mice were on 
different genetic backgrounds [107,108]. 
Here we report, for the first time, a direct comparison between an NMD- Bmpr2 mutation 
and an NMD+ Bmpr2 mutation in three different models of experimental PH.  We evaluated the 
effects on disease progression by assessing hemodynamic and molecular parameters and found 
that the NMD- Bmpr2 mice (Bmpr2Ex2/+) have basal signaling defects in phospho-eNOS, an 
increase in RVSP (the equivalent of mPAP in mice), and an increase in the number of 
obstructive vascular lesions.  Taken together, these data show that NMD- and NMD+ Bmpr2 
mutations likely have different mechanisms of disease pathogenesis, likely due to the expression 
of a mutant Bmpr2 protein product in the NMD- Bmpr2 mutants and a haploinsufficient effect in 
the NMD+ Bmpr2 mutants.         
Materials and Methods 
Ethics Statement 
Mice used in studies were approved by the Vanderbilt University Institutional Animal 
Care and Use Committee (Dr. Ron Emeson, IACUC chair) under protocol number M/11/015 and 
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were adherent with the National Institutes of Health guidelines for care and use of laboratory 
animals under Vanderbilt animal welfare assurance licence number A3227-01. 
Mouse lines 
 Bmpr2Ex2/+ mice were described previously [108].  Studies were approved by the 
Vanderbilt University Institutional Animal Care and Use Committee (see above for ethics 
statement).  Mice were backcrossed onto a C57Bl/6J background for more than 9 generations.  
Genotyping was performed by PCR from ear punch DNA using the following primers: Common 
forward CCATGCTCTTTTGAAGATGG; Wild type reverse: GTCCCCTTTTGATTTCTCCCA 
(producing a 1kB WT product); and mutant reverse: GGCCGCTTTTCTGGATTCATC 
(producing a 700bp mutant product).   
 Bmpr2+/- mice were described previously in [107].  Genotyping was performed by PCR 
from ear punch DNA using three primers: Common forward GCTAAAGCGCATGCTCCAGA 
CTGCCTTG; Wild type reverse TCACAGCATGAACATGATGGAGGCG G (producing a 200 
bp product); and mutant reverse AGGTTGGCCTGGAACCTGAGGAAATC (producing a 260 
bp product). 
Experimental models of PH 
 Mice were exposed to chronic hypoxia (10% O2) for three weeks.  RVSP was evaluated 
as a parameter of cardiac function.  The serotonin and chronic hypoxia model of PH was adapted 
from [98].  Briefly, adult male and female (because there were no sex differences in this model 
of experimental PH [98]) WT, Bmpr2+/−, or Bmpr2Ex2/+ mice, 8-12 weeks of age weighing 20 g 
+/- 5 g,  received serotonin (Sigma) via intraperitoneal osmotic minipumps (Model 1002, Alzet) 
at a rate of 5 nmol/h over 2 weeks, or saline vehicle.  At 2 weeks the pumps were 
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replaced.   After recovery, animals were maintained in room air (21% O2) or in a hypoxic 
chamber (10% O2) for 5 weeks.   
First characterized in rats [109], the VEGFR2 inhibitor Sugen 5416 and chronic hypoxia 
model has recently been adapted to mice [110].  Adult male WT, Bmpr2+/-, or Bmpr2Ex2/+ mice, 
8-12 weeks of age weighing 20 g +/- 5 g,  were injected subcutaneously with SU5416 (Tocris) 
suspended in CMC (0.5% [w/v] carboxymethylcellulose sodium (Sigma), 0.9% [w/v] sodium 
chloride (Sigma), 0.4% [v/v] polysorbate 80 (Sigma), 0.9% [v/v] benzyl alcohol (Sigma) in 
deionized water) once per week at 20 mg/kg for 3 weeks.  The animals were maintained in room 
air (21% O2) or in a hypoxia chamber (10% O2) for the duration of the 3 weeks.  Hemodynamics 
were assessed 1 week after the last injection of SU5416, at 4 weeks.   
Hemodynamic assessment of experimental PH 
 Mice were anesthetized with tribromoethanol (Avertin, Sigma) at 375 mg/kg body 
weight.  To evaluate PAP, right ventricular systolic pressure was measured directly by right heart 
catheterization with a PVR-1035 pressure/volume catheter (Millar Instruments) through the 
surgically exposed right jugular vein.  Pressure data was recorded for 10-20 seconds using the 
MPVS-300 System (Millar Instruments) and analyzed using LabChart Pro7 software (ADI 
instruments).  The left lung was clamped and removed then snap frozen for later use in protein 
expression analysis.  The right lung was inflated with 10% formalin, fixed overnight, and then 
used for immunohistochemical analysis.  The heart was removed for later analysis of right 
ventricle hypertrophy.    
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Assessment of RV hypertrophy 
 The right ventricle was dissected from the left ventricle and septum, dried for 2 days at 
55oC, and then weighed.  Right ventricle hypertrophy was measured by dividing the weight of 
the right ventricle by the weight of the left ventricle and septum.   
Assessment of vascular remodeling 
 Peripheral muscularization assessment was performed while blinded to genotype.  
Sections were stained by co-immunofluorescence using mouse anti--Smooth Muscle actin 
(SMA) at a dilution of 1:50 (Sigma) and rabbit anti-von-Willebrand Factor (Dako) at a dilution 
of 1:400.  Peripheral vessels were defined as small vessels less than 100 M, distal to 
muscularized bronchioles.  Vessels were classified as non-muscularized, partially muscularized, 
or fully muscularized. 
Assessment of vascular cell proliferation 
 Assessment was made while blinded to genotype.  Co-immunofluorescence using rabbit 
anti-PCNA (Santa Cruz) and anti--SMA were used to identify actively proliferating vascular 
cells.  If PCNA fluorescence was internal to -SMA expressing cells, it was counted as a PCNA 
positive endothelial cell.     
Assessment of obstructive lesions  
 H&E staining of lung tissue was performed in the Translational Pathology Shared 
Resource.  Assessment of lesions was performed while blinded to genotype.  Lesions were 
defined as a greater than 25% blockage or obstruction of the pulmonary vessel lumen by cells 
other than red blood cells.   
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Western blot analysis 
 Lung tissue was homogenized using a Fisherbrand motorized tissue homogenizer.  
Homogenized tissue was lysed in ice cold lysis buffer (LB) made up of 25mM HEPES, 150mM 
NaCl, 5mM EDTA, 1% Triton X-100, 10% glycerol containing proteinase inhibitor cocktail and 
phosphatase inhibitor cocktails 2 and 3 (Sigma).  Protein concentration was measured using the 
DC Protein Assay (Bio-Rad).  Mouse monoclonal anti-BMPR2 (clone 18, BD Biosciences) anti-
phospho-eNOS (Tyr 495), anti-eNOS (BD Biosciences) and anti--actin (Sigma-Aldrich); rabbit 
polyclonal anti-phospho-Smad1 (Ser463, Ser 465) /5(Ser 463, 465) /8(Ser 426, 428), anti-
phospho-p38 and anti-phospho-Erk1/2 (Thr 202, Tyr 204), phospho-eNOS (Ser 1177) (Cell 
Signaling), anti-Id1 (BioCheck) were used in signaling analysis.  All primary antibodies were 
used at a dilution of 1:1000 in 5% nonfat dry milk in TBST (25 mM Tris, 1 M NaCl, 1% Tween 
20), excepting phospho-specific antibodies which were diluted 1:1000 in 5% BSA in TBST.  
Secondary antibodies were diluted 1:2000 in 5% nonfat dry milk in TBST.   
Statistics 
Statistical analyses were performed using one-way ANOVA with Multiple comparisons 
between groups and Bonferroni Comparison test correction post hoc with Graphpad Prism 5 
software.  Significance is indicated if p<0.05. 
Results 
Serotonin and chronic hypoxia causes an increase in right ventricular systolic pressure in mice 
expressing Bmpr2 mutations 
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 To assess if NMD+ and NMD- Bmpr2 mutations mitigated different effects we used 3 
experimental models of PH , chronic hypoxia [96,99], chronic infusion of serotonin and 5 weeks 
of hypoxia [98], and chronic hypoxia +SU5416.  We measured RVSP, a parameter in mice that 
is similar to the mPAP in humans and indicative of PH.  Mice that have RVSPs greater than 25 
mm Hg have PH.  Our findings revealed a modest increase in RVSP between mice in normoxia 
and chronic hypoxia but no significant differences between WT, Bmpr2+/-, and Bmpr2Ex2/+ mice 
(Figure 1 and 2).  Bmpr2+/-and Bmpr2Ex2/+ mutant mice infused with serotonin and placed in 
hypoxia had significant differences in RVSP compared to normoxic controls, but the NMD- and 
NMD+ Bmpr2 mice were not significantly different from each other or form WT mice. 
Bmpr2Ex2/+ mutants have increased RVSP in the SU5416 and hypoxia model of PH.  
The VEGFR2 inhibitor SU5416 and hypoxia model of PH, in addition to having more 
robust hemodynamic responses, undergoes extensive pulmonary vasculature remodeling similar 
to observed characteristics of human PH [110,111].  Unlike the serotonin model, we found that 
mice injected with CMC vehicle control and placed in hypoxia had a significant increase in 
RVSP compared to normoxic CMC vehicle control Bmpr2 mutant mice (Figure 2).  This is likely 
due to gender differences between models.  Female mice were used in combination with male 
mice in the serotonin and hypoxia model whereas only male mice were used in the SU5416 and 
hypoxia model.  Females are more susceptible to PH than males [3,112] and are often left out in 
experimental models of PH.  Similarly to the serotonin model, mice treated with SU5416 and 
placed in hypoxia had significantly increased RVSPs compared to normoxic controls-but with 
much higher pressures.  We found that Bmpr2Ex2/+ mice had significantly higher pressures 
compared to the Bmpr2+/- mice.  These findings indicate that there is a significant difference in  
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Figure 1.  RVSP in WT, Bmpr2+/-, and Bmpr2Ex2/+ mice exposed to serotonin (5HT) and 
hypoxia.  Data are means+/- SEM. WT normoxia n=7, Bmpr2+/-normoxia n=6, and 
Bmpr2Ex2/+normoxia n=8,  WT hypoxia n=7, Bmpr2+/-hypoxia  n=6, and Bmpr2Ex2/+hypoxia 
n=5, WT hypoxia+ 5HT n=8, Bmpr2+/-hypoxia + 5HT n=6, and Bmpr2Ex2hypoxia +5HT n=8.  
One-way ANOVA with post hoc Bonferroni correction for between group comparisons.  
*p<0.05.     
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Figure 2.  RVSP in WT, Bmpr2+/-, and Bmpr2Ex2/+ mice exposed to SU5416 and hypoxia.  
Data are means+/- SEM. WT normoxia n=9, Bmpr2+/-normoxia n=9, and Bmpr2Ex2/+normoxia 
n=8, WT hypoxia n=10, Bmpr2+/-hypoxia n=8, and Bmpr2Ex2/+hypoxia n=9, WT hypoxia+ 
SU5416 n=14, Bmpr2+/-hypoxia + SU5416  n=13, and Bmpr2Ex2/+ hypoxia +SU5416 n=9.  One-
way ANOVA with post hoc Bonferroni correction for between group comparisons.  *p<0.05 
Bmpr2+/- and Bmpr2Ex2/+normoxia vs. WT, Bmpr2+/-, and Bmpr2Ex2/+hypoxia. **p<0.05 WT 
hypoxia +SU5416 vs. Bmpr2Ex2/+hypoxia + SU5416, ***p<0.05 vs. Bmpr2+/- hypoxia + 
SU5416vs. Bmpr2Ex2/+hypoxia+ SU5416. ****p<0.05 Bmpr2+/- and Bmpr2Ex2/+ 
hypoxia+SU5416 vs. hypoxia, and #p<0.05 normoxia vs. hypoxia+ SU5416          
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Figure 3.  Hemodynamics of WT, Bmpr2+/-, and Bmpr2Ex2/+  Su5416+ hypoxia model of PH.  
A. RV/LV+S and B. Cardiac Output in WT, Bmpr2+/-, and Bmpr2Ex2/+ mice exposed to SU5416 
and hypoxia.  Data are means+/- SEM. For RV/LV+S WT normoxia n=9, WT hypoxia+ SU5416 
n=14, Bmpr2+/-hypoxia + SU5416  n=13, and Bmpr2Ex2/+ hypoxia +SU5416 n=9.  For CO n=4.  
One-way ANOVA with post hoc Bonferroni correction for between group comparisons.  
*p<0.05 WT normoxia vs. hypoxia + SU5416. 
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disease pathogenesis between all three models, and that each affects the Bmpr2 mutants 
differently.  Further characterization of experimental PH was carried out using the SU5416 and 
hypoxia model.   
SU5416 and hypoxia mice have worse hemodynamics compared to normoxic controls      
 RV hypertrophy is an assessment of right heart muscularization in response to increased 
pulmonary pressure caused by the constriction of the pulmonary vessels.  It is a way to assess a 
failing heart, and dysfunctional pulmonary circuit [113].  SU5416 and hypoxia WT, Bmpr2+/-, 
and Bmpr2Ex2/+ mice had significantly increased RV hypertrophy compared to WT normoxic 
controls, but not from each other (Figure 3A).  We next assessed the cardiac output in these mice 
using a pressure/volume catheter (Millar).  Mice treated with SU5416 and hypoxia showed a 
slight decrease in cardiac output (Figure 3B).  Taken together, this assessment of hemodynamics 
shows that the SU5416 and hypoxia model of PH causes severe PH, but there are no significant 
differences in RV hypertrophy or cardiac output between WT, Bmpr2+/-, and Bmpr2Ex2/+mice.   
Bmpr2+/- mice have increased vascular remodeling 
 To assess changes in vascular remodeling, we evaluated muscularization of the peripheral 
vessels (vessels under 100 m) (Figure 4A).  The WT, Bmpr2+/-, and Bmpr2Ex2/+ SU5416 and 
hypoxia mice had significant loss of non-muscularized peripheral vessels compared to WT 
normoxia control mice (Figure 4B).  Conversely, WT, Bmpr2+/-, and Bmpr2Ex2/+ SU5416 and 
hypoxia mice had a significant increase in muscularized vessels compared to WT controls.  There 
was no difference in muscularlized or nonmuscularized vessels between Bmpr2+/-and 
Bmpr2Ex2/+mice.  When muscularized vessels are further categorized as fully or partially 
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muscularized, SU5416 and hypoxia Bmpr2+/-mice have a significant increase in fully 
muscularized vessels in comparison to WT and Bmpr2Ex2/+mice.   
Increased vascular cell proliferation in SU5416 and hypoxia mice  
 Vascular cell proliferation is a key characteristic of PH.  Uncontrolled proliferation leads 
to obstruction of the vessels as well as to a decrease in the surface area of the vessels leading to 
increased RVSP [3].  Previous studies showed that 1 week after SU5416 injection and placement 
in hypoxia resulted in the highest expression of PCNA in pulmonary vascular cells [110].  Based 
on this, we evaluated proliferative responses in Bmpr2 mutant mice at 1 week.  PCNA co-
immunofluorescence with -SMA was used to identify proliferating cells [80,99,114].  PCNA 
positive cells were internal to the a-SMA stain and were identified as endothelial cells (Figure 
5A, arrows).  PCNA positive cells co-localized with -SMA, were identified as SMCs (Figure 
5B, arrowheads).  WT, Bmpr2+/-, and Bmpr2Ex2/+ SU5416 and hypoxia mice have a significant 
increase in the percentage of PCNA positive cells in the pulmonary vasculature (PCNA positive 
cells/total cells in vessel stained with DAPI) (Figure 5B).  Interestingly, the WT SU5416 and 
hypoxia mice have the largest increase in proliferating cells.  WT normoxia control mice have the 
lowest percentage of proliferating cells (Figure 5B) but most of the PCNA positive cells are 
SMCs (Figure 5C).  This is in contrast to the SU5416 and hypoxia mice, all of which have a 
higher percentage of proliferating ECs (Figure 5D).   
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Figure 4.  Peripheral vessel muscularization.  The lungs were isolated, pressure perfused, 
fixed, and 5-μm sections stained with antibodies for α-smooth muscle actin (SMA) and von 
Willebrand factor (vWF). One hundred pulmonary arterioles (<100 μm) per section were 
analyzed blinded to the source of tissue. A. 40x representative picture for WT Normoxia, WT, 
Bmpr2+/-, and Bmpr2Ex2/+mice exposed to SU5416 and hypoxia, n=5 per group.  B. Each vessel 
was assigned as either nonmuscularized (no α-SMA staining) or muscularized (α-SMA staining) 
C. Each vessel was assigned as either nonmuscularized (no α-SMA staining), partially 
muscularized, or fully muscularized (thick unbroken wall of smooth muscle), and then the 
percentage distribution of each calculated per group. Data are means+/- SEM. One-way ANOVA 
with post hoc Bonferroni correction for between group comparisons.  *p<0.05 WT normoxia vs. 
hypoxia + SU5416, **p<0.05 WT normoxia vs. hypoxia + SU5416, #p<0.05  Bmpr2+/- hypoxia 
+ SU5416 vs. WT and Bmpr2Ex2/+ hypoxia + SU5416.  Scale bar=50M. 
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Figure 5.  Evaluation of proliferation in pulmonary vasculature from mice treated with 
1wk of SU5416 and hypoxia.  The lungs were isolated, pressure perfused, fixed, and 5-μm 
sections stained with antibodies for α-smooth muscle actin (SMA) and proliferating cell nuclear 
antigen (PCNA). One hundred pulmonary arterioles (<100 μm) per section were analyzed 
blinded to the source of tissue. A. 40x representative picture for WT Normoxia, WT, Bmpr2+/-, 
and Bmpr2Ex2/+mice exposed to SU5416 and hypoxia, n=5 per group.  B. Percent cells 
proliferating in vessels.  Total PCNA positive cells divided by total nuclei per vessel (DAPI). C. 
SMC were stained with α-SMA.  Number of SMC-PCNA positive cells per total PCNA positive 
cells D. EC (cells interior to α-SMA stain).  Number of EC-PCNA positive cells per total PCNA 
positive cells.  Data are means+/- SEM. One-way ANOVA with post hoc Bonferroni correction 
for between group comparisons.  p<0.05 WT normoxia vs. hypoxia + SU5416.  Scale bar = 
100m.  White arrows=PCNA+ ECs, White arrowheads=PCNA+SMC.  
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Bmpr2Ex2/+  SU5416 and hypoxia mice an increased number of obstructive vascular lesions      
WT, Bmpr2+/- and Bmpr2Ex2/+ SU5416 and hypoxia mice have an increased number of 
vascular obstructions compared to WT normoxic controls (Figure 6A, B).  Vascular obstructions 
were defined as blockage or obstruction of greater than 25% of the pulmonary vessel lumen by 
cells other than red blood cells.  The Bmpr2Ex2/+ SU5416 and hypoxia treated mice also have 
significantly more obstructions than WT SU5416 and hypoxia mice (Figure 6B).  The decreased 
surface area and blood flow due to the vascular lesions could provide one explanation for the 
increased RVSP observed in the Bmpr2Ex2/+ SU5416 and hypoxia mice, and is suggestive of a 
more severe form of PH.  Evaluation of vessels per aveoli reveal no significant differences 
between WT, Bmpr2+/- and Bmpr2Ex2/+ SU5416 and hypoxia mice (6C).   
Basal signaling abnormalities in Bmpr2Ex2/+ mice 
 To evaluate the effects of different Bmpr2 mutants on signaling pathways, we 
homogenized lungs from 4 mice of each genotype.  The most striking difference was the 
significant reduction of phospho-S1177eNOS, phospho-T495eNOS, phospho-Erk1/2, and 
phospho-p38 in Bmpr2Ex2/+mice (Figure 7).  The Bmpr2+/- mice also have a significant 
reduction of phospho-S1177eNOS expression compared to WT mice.  Phospho-Smad1/5/8 is  
upregulated, although not significantly, in Bmpr2mutant mice.   
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Figure 6.  Evaluation of vascular obstructions in SU5416 and hypoxia.  The lungs were 
isolated, pressure perfused, fixed, and 5-μm sections stained with H&E. Each section was 
analyzed blinded to the source of tissue. A. 20x representative picture for WT Normoxia, WT, 
Bmpr2+/-, and Bmpr2Ex2/+mice exposed to SU5416 and hypoxia, n=5 per group.  Black arrows 
indicate areas of vascular lesions.  B. Average number of abnormalities per field.  50 fields per 
mouse were scored.  C. Number of vessels per 1000 aveoli.  Peripheral vessels and aveoli were 
counted until approximately 1000 aveoli was reached and expressed as vessels/aveoli. Data are 
means+/- SEM. One-way ANOVA with post hoc Bonferroni correction for between group 
comparisons.  *p<0.05 and **p<0.05 WT normoxia vs. hypoxia + SU5416.  ***p<0.05 
Bmpr2Ex2/+ hypoxia + SU5416 vs. WT hypoxia + SU5416.  Scale bar = 100m.   
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Bmpr2Ex2/+mice have decreased phospho-Smad1/5/8 expression after 1 week of SU5416 and 
hypoxia 
Bmpr2 mediates signaling responses to regulate vascular homeostasis [51].  We wanted 
to evaluate Bmpr2 signaling responses to 1) determine which pathways were altered in the 
SU5416 + hypoxia model, and 2) determine if the Bmpr2 mutants had similar signaling 
responses.  At 1 week after the initiation of SU5416 injections and hypoxia, although basally 
reduced in Bmpr2Ex2/+mice (Figure 7), phospho-1177eNOS, phospho-T495eNOS, phospho-
Erk1/2, and phospho-p38 expression are increased to levels similar to or greater than WT 
expression levels (Figure 8).  Phospho-Smad1/5/8, upregulated in basal conditions, is 
significantly downregulated in Bmpr2Ex2/+mice after 1 week of SU5416 and hypoxia.  The WT 
and Bmpr2+/- mice were not different from each other.  This reduction in Smad and elevation in 
eNOS was interesting because it showed that these pathways are fluctuating, but not in the same 
ways-suggesting that the protein product of Bmpr2Ex2/+ and Bmpr2+/- respond to different 
stimuli. 
Evaluation of signaling responses in WT, Bmpr2+/- and Bmpr2Ex2/+mice after 3weeks of SU5416 
and hypoxia and 1wk of hypoxia 
 We next wanted to evaluate signaling pathways after 3 weeks of SU5416 and hypoxia 
treatment with an additional 1 week of hypoxia to determine if Bmpr2 mutation type elicits 
different signaling effects in mice.  We found greater variability in signaling responses in WT, 
Bmpr2+/- and Bmpr2Ex2/+mice.  We found no significant differences between WT and Bmpr2 
mutants (Figure 9).  Taken together, Figures 7, 8, and 9 illustrate the dynamic and unique 
signaling responses in different Bmpr2 mutations over time.   
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Figure 7.  Aberrant signaling activity in whole lungs isolated from normoxic controls.  The 
lungs were isolated, homogenized, and lysed.  A. Western blots showing signaling pathway 
expression of common Bmp-mediated pathways.  B. Densitometry of western blots.  Data are 
means+/- SEM. One-way ANOVA with post hoc Bonferroni correction for between group 
comparisons.  *p<0.05 WT vs. Bmpr2+/- , **p<0.05 vs. Bmpr2Ex2/+  
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Figure 8.  Aberrant signaling activity in whole lungs isolated after 1 week SU5416 and 
hypoxia.  The lungs were isolated, homogenized, and lysed.  A. Western blots show expression 
of common Bmp-mediated pathways.  B. Densitometry of western blots.  Data are means+/- 
SEM. One-way ANOVA with post hoc Bonferroni correction for between group comparisons.  
*p<0.05 WT vs. Bmpr2Ex2/+  
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Figure 9.  Aberrant signaling activity in whole lungs isolated from mice after treatment 
with 3 weeks SU5416 and hypoxia.  The lungs were isolated, homogenized, and lysed.  A. 
Western blots showing signaling pathway expression of common Bmp-mediated pathways.  B. 
Densitometry of western blots.  Data are means+/- SEM. One-way ANOVA with post hoc 
Bonferroni correction for between group comparisons.   
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Discussion 
 We report for the first time the in vivo analysis of an NMD- and an NMD+ Bmpr2 
mutation on the same genetic background.  Using the chronic hypoxia and serotonin+hypoxia 
experimental models of PH we show that serotonin and hypoxia modestly, but significantly, 
increase the RVSP in Bmpr2+/-and Bmpr2Ex2/+mice compared to Normoxia controls.  This 
finding indicates that serotonin-mediated responses in Bmpr2+/-and Bmpr2Ex2/+mice are not 
differentially effected by mutation type.  The Bmpr2Ex2/+mice do not show increased 
susceptibility to this model compared to Bmpr2+/- mice, indicating that the deletion of Exon2 
likely does not interface with pathways regulating serotonin. 
 However, in contrast to the serotonin model, Bmpr2+/- mice Bmpr2Ex2/+mice have 
significant differences in the SU5416 and hypoxia model of PH.  Bmpr2Ex2/+ mice had 
significantly increased RVSPs compared to the Bmpr2+/- mice.  Furthermore, Bmpr2Ex2/+mice 
have more vascular lesions in response to SU5416 and hypoxia.  This indicates that the 
functional consequences of the deletion of Exon2 in the Bmpr2Ex2/+ mice, is exacerbated with 
VEGFR2 inhibition.   
Basal evaluation of signaling responses showed several key differences between mutants.  
Bmpr2Ex2/+mice have decreased expression of phospho-s1177eNOS and phospho-T495eNOS, 
phospho-Erk1/2, and phospho-p38Mapk and increased phospho-Smad1/5/8.  These results 
provide intriguing data about the signaling pathways in the Bmpr2Ex2/+mice that are already 
altered without added environmental stimuli.  Week 1 signaling data provides an interesting 
glimpse into the initial response capabilities of the Bmpr2Ex2/+ mutant to stimuli (SU5416 and 
hypoxia) as PH is developing in vivo.  In fact, phospho-Smad1/5/8, the canonical BMP-mediated 
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pathway, is reduced at this timepoint and phospho-eNOS, phospho-Erk1/2, and phospho-p38 that 
were significantly reduced basally, here are increased.  This suggests the impairment of the 
Bmpr2Ex2/+ mutant in regulating those signaling pathways, either because it is sequestered in the 
ER [84,115,116], is sequestering an interacting protein [116], or it is unable to provide or 
respond to biological feedback in response to VEGFR inhibition.  This is interesting because it 
indicates that not all Bmpr2 mutations respond in the same ways to the same stimuli.  This is 
significant because it provides a molecular basis to begin to understand what is observed in 
HPAH patients, that not all BMPR2 mutations lead to disease, and not all mutations affect 
patients in the same ways.  The exacerbated response to VEGFR2 inhibitor also provides an 
insight into what pathways the Bmpr2Ex2 mutant product might be involved in and affecting.   
 Interestingly, the SU5416 and hypoxia model showed significant increases compared to 
normoxia controls but not between Wt, Bmpr2+/-, Bmpr2Ex2/+ in RV hypertrophy and cardiac 
output.  It is important to note that the cardiac output measurement may be skewed.  Due to poor 
pressure/volume loop quality, only 4 of 8 mice per group produced sufficient data to determine 
cardiac output.  The mice that produced usable volume loops tended to have lower RVSPs, so the 
cardiac functions of mice with the most extreme RVSPs were unable to be used.  This may not 
give an accurate assessment of cardiac output in experimental PH.  One alternative would be to 
use echocardiography to assess the cardiac output of mice.  
  WT SU5416 and hypoxia mice have a significant increase in proliferating vascular cells.  
This data, in combination with the differences in RVSP in response to serotonin or SU5416 by 
the two Bmpr2 mutants, the increase in remodeling observed in Bmpr2+/-, and the differences in 
vascular abnormalities and signaling function in the Bmpr2Ex2/+ provide compelling evidence 
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that the WT, Bmpr2+/-, Bmpr2Ex2/+mice are responding to/have increased sensitivity to different 
mechanisms leading to the development of experimental PH.  In fact, this is observed in PAH 
patients [2,17,35,95,117].  Additionally, because of the number of BMPR2 mutations in HPAH 
patients, it is not unreasonable for mutations to present different phenotypes, dependent on if the 
mutant is able to produce a protein, and where in the protein the mutation occurs [104].  This 
comparison of Bmpr2 mutation types in a SU5416 hypoxia model of PH offers an exciting, 
novel, and initial step to understand the HPAH clinical data and the role of BMPR2 mutation in 
disease pathogenesis.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
 
CHAPTER III 
 
ABNORMAL TRAFFICKING OF ENDOGENOUSLY EXPRESSED BMPR2 MUTANT 
ALLELIC PRODUCTS IN PATIENTS WITH HERITABLE PULMONARY ARTERIAL 
HYPERTENSION 
 
Introduction 
Over 200 unique mutation sites have been identified throughout the open reading frame 
of the BMPR2 gene in HPAH patients [45,47].  The majority of these mutations are non-sense or 
frame-shift mutations, leading to degradation of an unstable mRNA by nonsense mediated 
mRNA decay (NMD positive mutation), ultimately leading to haploinsufficiency [104]. 
However, 40% of HPAH-associated BMPR2 mutations are mis-sense or in-frame deletion 
mutations, predicted to produce stable mRNA transcripts and express mutant protein products.  
Clinical data indicate that HPAH patients with these mutations have a more severe form of 
HPAH with reduced time until lung transplant and an earlier age of diagnosis[104], suggesting 
that these mutant protein products are expressed and may have dominant negative effects on 
BMPR2 function. Previous studies have characterized NMD negative BMPR2 mutations using 
heterologous over-expression systems. These data suggest that HPAH-associated missense 
mutations in the ligand binding and kinase domains of BMPR2 are unable to traffic to the cell 
surface [79,118], and that trafficking and signaling can be restored using chemical chaperones 
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[116]. These findings suggest that chemical chaperones, which correct folding and restore 
function of mutant protein products in a variety of heritable diseases including cystic fibrosis 
[119,120], might be used as disease modifying agents by restoring signaling function to some 
NMD negative BMPR2 mutations in patients with HPAH. However there is no documented 
evidence that NMD negative BMPR2 mutant proteins products are actually expressed 
endogenously in patients with HPAH, and no data to indicate whether chemical chaperones 
restore function in pulmonary vascular cells.  
In these studies, we evaluate endogenous expression and intracellular trafficking of 
BMPR2 mutant products in lymphocytes from an HPAH patient with an NMD negative BMPR2 
mutation expressing an in-frame deletion of BMPR2 EXON 2, and in pulmonary endothelial cells 
(PECs) from mice carrying the same mutation. We show that these mutant receptor products are 
expressed, abnormally trafficked to the cell surface and that these defects are corrected by 
treatment with chemical chaperones.  
Materials and Methods 
Ethics statement  
Mice used in endothelial cell studies were approved by the Vanderbilt University 
Institutional Animal Care and Use Committee (Dr. Ron Emeson, IACUC chair) under protocol 
number M/11/015 and were adherent with the National Institutes of Health guidelines for care 
and use of laboratory animals under Vanderbilt animal welfare assurance licence number A3227-
01. 
The Vanderbilt University Medical Center Institutional Review Boards approved use of 
control and HPAH patient-derived lymphocytes and participants gave informed written consent 
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for use of their lymphocyte cultures for study (IRB #9401"Genetic and Environmental 
Pathogenesis of PPH" RFA-HL-04-019, Dr. James A.S. Muldowney, chair, Institutional Review 
Board Health Sciences Committee #3). 
Mouse lines  
Endothelial cell lines were isolated from Bmpr2Ex2/+ mice (mice described previously 
[108]).  Studies were approved by the Vanderbilt University Institutional Animal Care and Use 
Committee (see above for ethics statement).  Mice were backcrossed onto a C57Bl/6J 
background for more than 9 generations.  Genotyping was performed by PCR from ear punch 
DNA using the following primers: Common forward CCATGCTCTTTTGAAGATGG; Wild 
type reverse: GTCCCCTTTTGATTTCTCCCA (producing a 1kB WT product); and mutant 
reverse: GGCCGCTTTTCTGGATTCATC (producing a 700bp mutant product).  To create the 
ciEC lines, Bmpr2Ex2/+ mice were bred with H-2Kb-tsA58 immorto mice (immorto mice 
described previously [121]).  Genotyping was performed as described above with the additional 
PCR primers for the immorto mice: forward: AGCGCTTGTGTCGCCATTGTATTC and 
reverse: GTCACACCACAGAAGTAAGGTTCC, producing a 1kb band.  
Chemicals and Reagents 
Sulfo-NHS-LC-Biotin and Streptavidin agarose conjugated beads (Pierce/Thermo 
Scientific); Dio-Ac-LDL (Biomedical Technologies Inc.); Endo-H and PNGase-F glycosidases 
(New England Biolabs); Human recombinant BMP-2 ( R&D Systems);  chemical chaperones 
sodium phenylbutyrate (4-PBA) and Sodium taurourdeoxycholic acid (TUDCA) (Sigma-
Aldrich).  The following antibodies were used for western blots: mouse monoclonal anti-BMPR2 
(clone 18, BD Biosciences) and anti--actin (Sigma-Aldrich); rabbit polyclonal anti-phospho-
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Smad1 (Ser463, Ser 465) /5(Ser 463, 465) /8(Ser 426, 428), anti-phospho-Akt(Ser 473), and anti-
phospho-Erk1/2 (Thr 202, Tyr 204) (Cell Signaling).  Affinity purified rabbit polyclonal anti-
BMPR2 antibodies were generated in house by immunizing rabbits with keyhole limpet 
hemocyanin conjugated peptide ASQNQERLCAFKDP (ASQ).  Secondary antibodies were anti-
mouse horseradish peroxidase (HRP) and anti-rabbit-HRP from KPL and Cell Signaling, 
respectively. 
Cell Culture 
Conditionally immortalized pulmonary endothelial cells (ciPECs) were isolated, passaged 
and maintained as previously described [80,81,99].  Briefly, cells were grown at 33oC in 
complete EGM-2MV media (LONZA) containing 10units/ml of interferon- (Peprotech).  Prior 
to experimental use, interferon- was removed and cells shifted from 33oC to 37oC for 2 days.  
HPAH patient-derived and normal control immortalized lymphocytes were isolated as previously 
described [46,122].  Cells were passaged and maintained in 1640 RPMI media (Gibco/Life 
Technologies) containing 20% fetal bovine serum (FBS) (Sigma).   
Isolation of Primary Pulmonary Endothelial Cells (PECs) 
Mouse pulmonary vasculature was perfused with phosphate buffered saline (PBS) 
containing 2mM EDTA followed by 0.25% Trypsin-EDTA through the right ventricle.  The 
lungs were excised, minced, placed in a 60mm dish with 0.25% Trypsin-EDTA and moved to a 
37o degree incubator for 20-30 minutes.  The lung block was removed and complete EGM-2MV 
containing 5% FBS was then added to the dish to neutralize trypsin.  Cells were centrifuged and 
re-suspended in fresh complete EGM-2MV with normacin (Invivogen).  The cell suspension was 
plated on 35mm dishes coated in 0.1% gelatin and grown for 2-3 days before media was 
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replaced.  The cells were identified as endothelial in origin based on morphology and Dio-AC-
LDL staining. Functional studies were carried out in the cells by passage 2. 
Western Blotting 
Cells were lysed in ice cold lysis buffer (LB) made up of 25mM HEPES, 150mM NaCl, 
5mM EDTA, 1% Triton X-100, 10% glycerol containing proteinase inhibitor cocktail and 
phosphatase inhibitor cocktails 2 and 3 (Sigma).  Protein concentration was measured using the 
DC Protein Assay (Bio-Rad).  Western blots were performed as previously described [114].  All 
primary antibodies were used at a dilution of 1:1000 in 5% nonfat dry milk in TBST (25mM 
Tris, 1M NaCl, 1% Tween 20), excepting phospho-specific antibodies which were diluted 
1:1000 in 5% BSA in TBST.  Secondary antibodies were diluted 1:2000 in 5% nonfat dry milk in 
TBST.   
Cell signaling and chemical chaperone treatment 
For signaling studies, cells were serum starved in EBM-2 media (Lonza) supplemented 
with 0.1% bovine serum albumin (BSA) for 16 hours and then treated with 10ng/ml BMP2 for 4 
hours.  EBM-2 is the basal media used to make complete EGM-2MV without addition of 
supplements, growth factors and FBS. Chemical chaperones were added to confluent monolayers 
of cells.  4-PBA and TUDCA were dissolved in water and added to cells at the indicated 
concentrations 48 hours and 5 hours prior to biotinylation, respectively.  For functional studies, 
primary PECs were treated with 4-PBA at 100M and 1mM for 48 hours.  Cells were serum 
starved for 16 hours, as described above, and treated with 10ng/ml of BMP2 for 4 hours before 
lysis.    
Glycosidase Sensitivity Assay 
45 
 
Cells were lysed in LB and immunoprecipitated using Protein G dynabeads (Life 
Technologies) conjugated to anti-BMPR2 antibody (Clone 18, BD) at room temperature for 15 
minutes, per the manufacturer’s directions. Immunoprecipitates were washed 3 times with LB, 
denatured using de-glycosylation buffer and subjected to Endo-H or PNGase-F digestion for 3 
hours in a 37o C before adding sample loading buffer, according to the manufacturer’s 
instructions (New England Biolabs).  
Biotinylation of Cell Surface Proteins 
Confluent monolayers were washed 2 times with ice-cold PBS and cell surface proteins 
labeled with 1mg/ml Sulfo-NHS-LC-Biotin in PBS for 30 minutes on ice and at 4oC.  Cells were 
washed 3 times with ice cold PBS and biotin labeling quenched by incubating cells with 100mM 
glycine in PBS for 5 minutes on ice. After this, cells were carefully washed in ice cold PBS to 
remove any residual glycine.  Cells were then lysed in LB and protein concentration determined.  
750g of lysate protein was incubated for 30 minutes with Streptavidin beads at 4oC, after which 
the beads were washed 3 times with LB before adding denaturing loading buffer and separating 
by SDS-PAGE.  Supernatant leftover after the streptavidin pull-down was incubated with anti-
BMPR2 antibody (Clone 18, BD) overnight at 4oC and then subjected to immunoprecipitation 
with Protein A/G Plus agarose beads (Santa-Cruz) for 30 minutes.  Immunoprecipitates were 
washed with LB and proteins eluted by adding sample loading buffer.  
Statistical Analysis 
Statistical analyses were performed using one-way ANOVA with Multiple comparisons 
between groups and Bonferroni Comparison test correction post hoc with Graphpad Prism 5 
software.  Significance is indicated if p<0.05.  
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Results 
Characterization of the BMPR2Ex2 mutant protein product in HPAH patient-derived 
lymphocytes 
To determine if NMD negative BMPR2 mutations are expressed and incorrectly 
trafficked to the cell surface in patients with HPAH, we evaluated BMPR2 protein expression in 
HPAH patient-derived lymphocytes [46,122].  Cultured immortalized lymphocytes were used 
because these cells are easily isolated and stored.  Additionally, we have a repository of frozen, 
HPAH patient-derived cultured lymphocytes at Vanderbilt from participants in the Vanderbilt 
Prospective Pulmonary Hypertension Research Cohort study [31,46,47,122-125].  For these 
studies we evaluated BMPR2 expression in lymphocytes derived from an HPAH patient from 
Vanderbilt PAH Family 108 (F108) who carry a splice site mutation predicted to result in an in-
frame deletion of BMPR2 EXON2, which encodes residues 26-82 of the 1038 full length BMPR2 
protein[46].  If expressed, the mutant product, BMPR2Ex2, would be distinguishable from the 
wild type allelic product by a mobility shift on western blot resulting from deletion of 56 amino 
acids encoded by EXON2.  We obtained lymphocytes from one normal control and one F108 
HPAH patient. The anti-BMPR2 antibody, Clone 18, which is a mouse monoclonal antibody 
raised against a recombinant fragment (residues 803-996) from the cytoplasmic tail of human 
BMPR2 (Fig. 10A), detected a strong 130-145 kDa wild type BMPR2 band in control and F108 
HPAH patient lymphocytes (Fig. 10B).  An additional weaker 120 kDa band was detected in 
F108 HPAH, but not in normal control cells.  To determine if the 120 kDa band was the 
predicted product resulting from in-frame deletion of BMPR2 EXON2 in F108 HPAH 
lymphocytes, we generated an affinity purified rabbit polyclonal anti-BMPR2 antibody, ASQ, 
raised against the peptide sequence of the first 14 amino acids encoded by BMPR2 EXON2 (Fig. 
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10A). The 130-145 kDa wild type BMPR2 band was detected in control and F108 lymphocytes, 
but the 120 kDa BMPR2 band was not detected in F108 cells using this antibody (Fig. 10C).  
These data indicate that lymphocytes from a F108 HPAH patient express a mutant BMPR2 
product resulting from an in-frame deletion of BMPR2 EXON2 (BMPR2Ex2).  
We next evaluated if the BMPR2Ex2 product was expressed at the cell surface.  For 
this, cell surface proteins were labeled with a membrane impermeable biotin and detected by 
streptavidin pull-down and western blot for BMPR2 using the Clone 18 anti-BMPR2 antibody. 
The 130-145 kDa wild type BMPR2 product was detected in the streptavidin pull-down in 
control and F108 cultured lymphocytes, but the 120 kDa BMPR2Ex2 band was not (Fig. 10D, 
right panel).  These data indicate that the BMPR2Ex2 mutant product resulting from the in-
frame deletion of BMPR2 EXON2 in the F108 HPAH patient does not correctly traffic to the cell 
surface in cultured lymphocytes.   
Characterization of the Bmpr2Ex2 product in pulmonary endothelial cells from Bmpr2Ex2/+ 
mice 
To evaluate expression and trafficking of the same, endogenously expressed, 
BMPR2Ex2 mutant product in a more physiologically relevant cell type, we isolated 
conditionally immortalized pulmonary endothelial cells (ciPECs) from Bmpr2Ex2/+ mice.  
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Figure 10.  HPAH patient-derived lymphocytes express mutant BMPR2 products. A, 
Schematic of the BMPR2 protein.  Areas recognized by the anti-BMPR2 antibodies clone 18 
and ASQ are indicated by black arrows.  Exons 1-13 are represented by alternating gray and 
white boxes, and numbers indicate corresponding amino acids.  LBD, represents the ligand 
binding domain, TM the transmembrane domain, KD the kinase domain and CT the cytoplasmic 
tail.  B, Detection of BMPR2 products in HPAH patient-derived lymphocytes, image 
representative of three experiments.  Western blot using anti-BMPR2 antibody, Clone 18. A 130-
145 kDa wild type BMPR2 product (WT) was detected in normal control and Family 108 (F108) 
HPAH patient-derived lymphoblasts.  F108 cells expressed an additional 120 kDa BMPR2 
mutant product (Ex2).  C, Representative western blot from three experiments using the ASQ 
anti-BMPR2 antibody. The 130-145 kDa product was detected in both control and F108 
lymphocytes, but the 120 kDa band was not detected.  D, Cell surface expression of BMPR2 in 
HPAH patient-derived lymphocytes labeled with a membrane impermeable biotin.  Experiment 
replicated three times.  Left panel, input cell lysates before the streptavidin pull-down. Right 
panel, cell surface proteins detected in streptavidin pull-down by Western blot using Clone 18 
anti-BMPR2 antibody.  A 130-145 kDa wild type BMPR2 product was detected in control and 
F108 cultured lymphocytes in streptavidin pull-down but not 120kDa BMPR2Ex2 mutant 
product. 
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Figure 11.  Characterization of the endogenously expressed Bmpr2 mutant product in 
pulmonary endothelial cells from Bmpr2Ex2/+ mice.  Studies were performed using 
conditionally immortalized PECs (ciPECs) isolated from wild type control and Bmpr2Ex2/+ mice 
and replicated at least three times.  A, Western blot using the Clone 18 anti-BMPR2 antibody in 
wild type (WT) and Bmpr2Ex2/+ (Ex2/+) ciPEC lysates.  Both cell lines expressed a 150 kDa 
wild type Bmpr2 product (WT). Bmpr2Ex2/+ ciPECs also expressed a 130 kDa product (Ex2).  
B, Western blot using ASQ anti-BMPR2 antibody.  Wild type control and Bmpr2Ex2/+ ciPECs 
expressed 150 kDa WT Bmpr2, but the 130 kDa product was not detected.  C, Cell surface 
expression of Bmpr2 in ciPECs.  ciPECs were labeled with membrane impermeable biotin and 
cell surface expression of Bmpr2 detected in streptavidin pull-down of cell lysates. Anti-BMPR2 
Clone 18 antibody detected the 150 kDa wild type Bmpr2 in control and Bmpr2Ex2/+ ciPECs 
after streptavidin pull-down but not the 130kDa Bmpr2Ex2 mutant product.  Lower panel, 
Western blot for Bmpr2 in the supernatant remaining after depletion of cell surface proteins by 
streptavidin pull-down.  The ratios of 150 kDa WT Bmpr2 and the 130 kDa Bmpr2Ex2 mutant 
band intensities in Bmpr2Ex2/+ ciPECs supernatants after depletion of cell surface proteins are 
indicated below the lower panel.  
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Bmpr2Ex2/+ mice carry the same, heterozygous in-frame deletion of Exon 2 found in F108 
HPAH patients [108]. The anti-BMPR2 antibody Clone 18 detected a 150 kDa band in control 
(wild type) and Bmpr2Ex2/+ ciPECs, but an additional 130 kDa band was only detected in the 
Bmpr2Ex2/+ ciPECs (Fig. 11A). To determine if the 130 kDa band was the predicted product 
resulting from an in-frame deletion of Bmpr2 Exon2, we performed western blot analysis using 
the anti-BMPR2 antibody ASQ, raised against the peptide sequence in Exon2 (Fig. 10A).  The 
wild type 150kDa Bmpr2 band was detected in both the control and Bmpr2Ex2/+ ciPECs, but the 
130kDa product was not detectable in the Bmpr2Ex2/+ciPECs using this antibody (Fig. 11B).  
These data indicate that Bmpr2Ex2/+ ciPECs expressed high levels of the Bmpr2Ex2 mutant 
product, which is detected as a 130 kDa band on western blot and is distinct from the 150 kDa 
wild type Bmpr2 product.  
We performed cell surface biotinylation studies to determine whether the BmprEx2 
mutant product was expressed at the cell surface of Bmpr2Ex2/+ciPECs. The 150 kDa wild type 
product was detected in the streptavidin pull-down in both control and Bmpr2Ex2/+ ciPECs 
(Figure 11C).  In contrast, the 130 kDa Bmpr2Ex2 mutant product was not detected in the 
streptavidin pull-down.  Additionally, while there was reduced expression of the wild type 
Bmpr2 protein in control and Bmpr2Ex2/+ ciPECs in the supernatant remaining after depletion of 
cell surface biotinylated proteins by streptavidin pull-down, expression of the 130kDa 
Bmpr2Ex2 mutant product was not reduced (Fig. 11C, lower panel).   These data indicate that 
like the 120 kDa BMPR2Ex2 product in F108 HPAH patient cultured lymphocytes, the 130 
kDa Bmpr2Ex2 mutant product does not traffic to the cell surface in Bmpr2Ex2/+ ciPECs.  
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Differential glycosidase sensitivity of the Bmpr2Ex mutant product 
We used N-linked glycosidases to determine if the Bmpr2Ex2 mutant product was able 
to traffic correctly through the endoplasmic reticulum (ER) and Golgi apparatus.  N-linked 
glycosylated proteins that are processed in the ER are sensitive to Endo-H glycosidase, but 
become resistant to Endo-H once the glycoprotein has passed through to the trans-Golgi [126]. 
In contrast, PNGase-F de-glycosylates all N-linked glycosylated proteins irrespective of their 
maturation state. This sensitivity to glycosidase digestion can be detected by a change in protein 
mobility resulting from cleavage of glycan moieties. As expected, the 150 kDa wild type Bmpr2 
product in control and Bmpr2Ex2/+ ciPECs underwent a mobility shift after treatment with 
PNGase-F, but was resistant to Endo-H digestion (Fig. 12). In contrast, the 130 kDa Bmpr2Ex2 
mutant product underwent a mobility shift after digestion with PNGase-F and Endo-H 
(Ex2>Ex21).  This indicates that wild type Bmpr2 is correctly processed through the ER and 
Golgi but that the 130 kDa Bmpr2Ex2 mutant product is likely to be retained in the ER.    
Chemical chaperones restore trafficking of the Bmpr2Ex2 mutant product to the cell surface 
Since the retention of mutant protein in the ER is often a consequence of incorrect protein 
folding [127], we wanted to evaluate the effects of two chemical chaperones known to aid in 
protein folding, 4-PBA and TUDCA [119,120,128-133] , on trafficking of the Bmpr2Ex2 
mutant product to the cell surface. Bmpr2Ex2/+ ciPECs treated with increasing concentrations of 
4-PBA show a dose-dependent increase expression of the 130kDa Bmpr2Ex2 mutant product in 
the streptavidin pull-down (Fig 13A/B).  Treatment with 4-PBA also increased the cell surface 
expression of the 150 kDa wild type Bmpr2 protein in Bmpr2Ex2/+ ciPECs, but to a relatively 
lesser extent than Bmpr2Ex2. An aliquot of cell lysates taken before the streptavidin pull-down  
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Figure 12.  Differential N-linked glycosidase sensitivity of wild type Bmpr2 and 
Bmpr2Ex2 mutant products.   Wild type control and Bmpr2Ex2/+ ciPEC lysates were 
immunoprecipitated and digested with N-linked glycosidases Endo-H or PNGase-F.  The 150 
kDa wild type Bmpr2 bands in both control and Bmpr2Ex2/+ ciPECs were sensitive to PNGase-F 
digestion, determined by a 15 kDa mobility shift (WT>WT1), but were insensitive to Endo-H 
digestion.  Unlike wild type Bmpr2, the 130 kDa Bmpr2Ex2 mutant product in Bmpr2Ex2/+ 
ciPECs was sensitive to Endo-H digestion (Ex2>Ex21).   
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Figure 13. Chemical chaperones partially restore Bmpr2Ex2 mutant product expression 
at the cell surface.  A, Cell surface expression of Bmpr2Ex2 in Bmpr2Ex2/+ ciPECs treated 
with 4-PBA. Bmpr2Ex2/+ ciPECs were treated for 48 hours with 100uM, 250uM, 500uM or 
1mM of 4-PBA. Monolayers were then labeled with membrane impermeable biotin and 
biotinylated cell surface proteins pulled-down with streptavidin agarose beads.  Western Blot 
was performed with Clone 18 anti-BMPR2 antibody. The 150 kDa wild type Bmpr2 product was 
detected in the streptavidin pull-down in control and Bmpr2Ex2/+ ciPECs, but the 130 kDa 
Bmpr2Ex2 mutant product was not detected. After treating with the chemical chaperone 4-
PBA, the 130kDa Bmpr2Ex2 mutant product was detected and there was increased expression 
of the wild type Bmpr2 product in the streptavidin pull-down. Numbers shown below the upper 
panel indicate the ratio of the 130 kDa Bmpr2Ex2 band before and after treatment with 4-PBA.  
Lower panel, expression of wild type Bmpr2 and Bmpr2Ex2 in ciPEC cell lysates with 4-PBA 
treatment. B, Quantification of wild type Bmpr2 and Bmpr2Ex2 band densities after 4-PBA 
treatment relative to untreated controls from three independent experiments, standard error is 
indicated.  C, Cell surface expression of Bmpr2Ex2 in Bmpr2Ex2/+ ciPECs treated with 
TUDCA. Wild type and Bmpr2Ex2/+ ciPECs were treated for 5 hours with 50uM 100uM, 250uM 
or 500uM of TUDCA. Streptavidin pull-down shows that the 130kDa Bmpr2Ex2 mutant 
product was partially restored at the cell surface and there was a slight increase in wild type 
Bmpr2 with TUDCA treatment (1.4 fold increase with 500M TUDCA versus untreated cells). 
Numbers shown below the upper panel indicate the ratio of the 130 kDa Bmpr2Ex2 band 
before and after treatment with TUDCA Lower panel, expression of wild type Bmpr2 and 
Bmpr2Ex2 in ciPEC cell lysates with TUDCA treatment. D, Quantification of wild type Bmpr2 
and Bmpr2Ex2 band densities after TUDCA treatment relative to untreated controls from three 
independent experiments.  
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showed no change in expression of wild type Bmpr2 or Bmpr2Ex2 with the addition of 4-PBA 
(Fig. 13A, lower panel).  An additional chemical chaperone, TUDCA added to cells prior to 
biotinylation also increased cell surface expression of the 130kDa Bmpr2Ex2 mutant protein in 
Bmpr2Ex2/+ ciPECs (Fig. 13C/D). There was also a small increase in cell surface expression of 
wild type Bmpr2 after treatment with TUDCA (a 1.4 fold increase with 500M TUDCA versus 
untreated cells).  These data indicate that chemical chaperones increase cell surface expression of 
Bmpr2Ex2 in Bmpr2Ex2/+ ciPECs, and suggest that ER retention of Bmpr2Ex2 results from 
mis-folding of the mutant protein.  
BMP signaling defects in primary pulmonary endothelial cells from Bmpr2Ex/+ mice 
To determine the functional effects of the Bmpr2Ex2/+ mutation on BMP-mediated 
signaling responses, we evaluated BMP signaling in early passage primary pulmonary 
endothelial cells (PECs).  For this, six separate PEC isolates were prepared from 3 wild type 
control and 3 Bmpr2Ex2/+ mice.  There was a significant decrease in BMP-stimulated phospho-
Smad1/5/8 expression in Bmpr2Ex2/+ PECs associated with reduced basal and BMP-induced Id1 
expression (Fig. 14A/B/C).  There was also an increase in phospho-Erk1/2 expression in 
Bmpr2Ex2/+ PECs (Fig. 14A/D) but no significant change in phospho-Akt (Fig. 14A/E).  These 
studies indicate that Bmpr2Ex2/+ PECs exhibit BMP signaling defects.   
Chemical Chaperone 4-PBA restores BMP signaling defects in Bmpr2Ex2/+ PECs 
To determine whether restoration of cell surface expression of Bmpr2Ex2 restores defective 
BMP signaling in Bmpr2Ex2/+ PECs, we evaluated BMP signaling primary PECs isolates 
obtained from 1 wild type control and 3 Bmpr2Ex2/+ mice treated with 4-PBA (Fig. 15A) 
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Figure 14. BMP signaling defects in primary pulmonary endothelial cells from Bmpr2Ex2/+ 
mice.  Primary PECs were isolated from 3 different wild type control (WT) and 3 Bmpr2Ex2/+ 
mice (Ex2).  A,Western blot of cell lysates isolated from wild type control (W1-W3) and 
Bmpr2Ex2/+ (E1-E3) PECs treated with 10ng/ml BMP2 for 4 hours. Antibodies indicated on the 
right. Densitometry for phospho-Smad1/5/8 (B), Id1 (C), pERK1/2 (D) and pAKT bands (E). 
Results expressed as mean +/- SEM, 3 per group. One-way ANOVA with post hoc Bonferroni 
correction, p<0.05 *WT +/-BMP2; **Ex2+/-BMP2; ***WT vs. Ex2.  Experiment and 
isolation of primary PECs was replicated four times.   
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Figure 15. Treatment with 4-PBA rescues signaling defects in Bmpr2Ex2/+ pulmonary 
endothelial cells. Individual primary PECs isolates obtained from 1 wild type control and 3 
Bmpr2Ex2/+ mice were treated with 1mM 4-PBA for 48 hours followed by BMP2 treatment for 4 
hours, as indicated. A. Western blot for phospho-Smad1/5/8 and Id1 shows 4-PBA restores 
phospho-Smad1/5/8 and Id1 expression in Bmpr2Ex2/+ PECs to expression levels similar to 
BMP-stimulated WT PECs.  B. Densitometry for phospho-Smad1/5/8 and C. Id1 expressed as 
ratio to total Smad1 and -actin respectively.  Results expressed as mean +/- SEM of three 
individual PEC isolates per group. One-way ANOVA with post hoc Bonferroni correction, 
p<0.05 * Ex2/+ +BMP2 vs. Ex2/+ +BMP2+4-PBA. 
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4-PBA restored BMP2 induced Smad1/5/8 phosphorylation (Fig. 15B) and BMP-induced Id1 
protein expression in Bmpr2Ex2/+ PECs to a level comparable to that seen in wild type PECs 
treated with BMP2  (Fig. 15C). These data indicate that treatment with the chemical chaperone 
4-PBA restores the defective BMP-Smad/Id1 signaling axis in Bmpr2Ex2/+ PECs.  
Discussion 
In these studies, we provide the first evidence that an NMD negative BMPR2 mutation 
found in patients with HPAH is expressed endogenously, and that this mutant protein product is 
mis-folded and incorrectly trafficked to the cell surface.  We also show that chemical chaperones 
partially restore cell surface expression of the same Bmpr2 mutant product in pulmonary 
endothelial cells from mice carrying the same heterozygous germ line mutation, and that 
treatment with chemical chaperones rescues the associated BMP signaling defects in these cells. 
These data provide the first evidence for the therapeutic use of chemical chaperones to correct 
endogenous signaling defects resulting from mis-folded BMPR2 mutant products in patients with 
HPAH.     
Our studies focus on the expression and trafficking of these BMPR2 mutant products in 
pulmonary endothelial cells from Bmpr2Ex2/+ mice since BMPR2 is highly expressed in 
endothelial cells in the pulmonary vasculature, and endothelial expression of BMPR2 has been 
implicated in maintaining normal pulmonary vasculature tone and 
integrity[44,78,89,99,100,134].  We have also previously shown that mice with heterozygous in-
frame deletion of Bmpr2 Exon2 (Bmpr2Ex2/+) have reduced endothelium-dependent vasodilator 
responses in the pulmonary vasculature [99], and approximately 30% of mice with conditional 
ablation of Bmpr2 in endothelial cells develop spontaneous pulmonary hypertension [100]. These 
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findings suggest that endothelial BMPR2 plays an important role in the regulating pulmonary 
vascular function, and suggests strategies to correct BMP signaling in pulmonary endothelial 
cells may have beneficial effects on the pulmonary vasculature in mice and HPAH patients with 
BMPR2 mutations.  
We found that the Bmpr2Ex2 mutant product was expressed at high levels in pulmonary 
endothelial cells isolated from Bmpr2Ex2/+ mice.  The identity of this band was verified as the in-
frame deletion of Exon2 by using an antibody raised against the peptide sequence encoded by 
BMPR2 Exon2 (ASQ).  This in-frame deletion of Exon2 is also expressed in the F108 HPAH 
patient-derived lymphocytes.  However, there are differences in mobility of both wild type 
BMPR2 and the BMPR2Ex2 products in mouse ciPECs and cultured human lymphocytes. This 
is likely due to cell-type dependent differences in post-translational modifications/glycosylation 
of BMPR2. In addition, unlike F108 HPAH patient–derived lymphocytes, the presumed 
Bmpr2Ex2 mutant product in Bmpr2Ex2/+ ciPECs had an expression level similar to the 150 
kDa wild type Bmpr2 product. This indicates that there are cell-type dependent differences in 
expression of the mutant allelic products, and that high levels of Bmpr2Ex2 expression in 
endothelial cells may exert more profound effects on cellular function than in different cell types. 
Cell surface biotinylation and N-glycosidase sensitivity assays indicate that the Bmpr2Ex2 
mutant product does not traffic correctly to the cell surface and is retained in the ER. 
Additionally, chemical chaperones 4-PBA and TUDCA, agents that are known to aid in protein 
folding [119,120,128-133], partially restore trafficking of the Bmpr2Ex2 mutant product to the 
cell surface. These findings suggest that the Bmpr2Ex2 is retained in the ER as a result of mis-
folding of the mutant product. Since deletion of Exon2 in Bmpr2Ex2 results in a loss of 3/10 
cysteine residues located in the ligand-binding domain of Bmpr2, it is likely that mis-folding 
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occurs as a result of a breakdown in paired cysteine disulfide bond formation which is required 
for correct Bmpr2 structure and folding in the ER [135-138].  
Our data suggest that chemical chaperones may be used to correct BMP signaling defects 
in HPAH patients with NMD negative BMPR2 mutations. Functional studies show that 4-PBA 
treatment can restore CFTR receptor F508 mutant trafficking and function in cells derived from 
Cystic Fibrosis (CF) patients [120], and 4-PBA has recently been used in clinical trials as a 
chemical chaperone to treat CF [139,140]. Treatment with chemical chaperones like 4-PBA aid 
in protein folding and trafficking to the cell surface; however it is important to note that there are 
a number of NMD negative BMPR2 mutations located in regions of the protein that would not 
benefit from trafficking to the cell surface.  For example, mutations located in the kinase domain 
or cytoplasmic tail domains of BMPR2 in particular may not benefit from chaperone treatment.  
For this strategy to work in HPAH patients with NMD negative BMPR2 mutations, the mutations 
must allow at least partial BMPR2 function when the mutant product is expressed at the cell 
surface. Correcting a protein-folding defect of an HPAH NMD negative BMPR2 mutant product 
that has dominant negative activity when expressed at the cell surface might have adverse effects 
on BMP signaling. This has been demonstrated with the kinase inactive HPAH BMPR2 C483R 
mutation in in a heterologous over-expression system [116], but still needs to be evaluated 
endogenously in HPAH patient-derived cells. In the case of Bmpr2Ex2, correction of BMP 
signaling defects by chemical chaperones may be occurring through two non-mutually exclusive 
mechanisms. While the Bmpr2Ex2 mutation interferes with the structure of the ligand-binding 
domain of the receptor (and presumably therefore interferes with ligand binding to the receptor), 
Bmpr2Ex2 may still participate in functional hetero-tetrameric complexes with wild type 
BMPR2 and other BMP Type 1 receptors that can independently directly engage BMP ligands at 
61 
 
the cell surface. Interestingly, 11% of NMD negative BMPR2 mutations are in the ligand-binding 
domain of BMPR2 [45], and may similarly benefit from corrected trafficking to the cell surface. 
However, in addition to restoring cell surface expression of the mutant allelic product, our data 
show that 4-PBA, and to a lesser extent TUDCA, increase cell surface expression of wild type 
Bmpr2 in Bmpr2Ex2/+ ciPECs. Since mis-folding of Bmpr2Ex2 may trap some wild type 
Bmpr2 in the ER, it is possible that this effect is a direct consequence of 4-PBA-dependent 
correction of the cell surface trafficking defect of the mutant allele. Given that expression levels 
of Bmpr2 have been shown to be important in maintaining normal signaling function [43,125], 
this increase in expression of wild type Bmpr2 protein at the cell surface may account for the 
restoration in BMP signaling in Bmpr2Ex2/+ ciPECs after treatment with chemical chaperones. 
However, irrespective of the mechanisms restoring BMP signaling in Bmpr2Ex2/+   ciPECs, our 
data indicate that there may be a subset of HPAH patients with NMD negative BMPR2 mutations 
that show beneficial responses to protein folding agents.  Further analysis of endogenous BMPR2 
mutant product folding and signaling defects in HPAH patients carrying different NMD negative 
BMPR2 mutations will have to be performed to determine which patients might benefit from this 
therapy. 
Our studies provide the first evidence that chemical chaperones can be used to rescue 
BMP signaling defects associated with endogenously expressed NMD negative HPAH BMPR2 
mutations in the pulmonary endothelium. Additionally, the chemical chaperones we evaluated, 4-
PBA and TUDCA, are FDA-approved drugs and commercially available supplements, 
respectively, and are in clinical trials for other diseases caused by mis-folded proteins [139-141]. 
Therefore, while further analysis of endogenous BMPR2 mutant product folding and signaling 
defects in HPAH patients will have to be performed to determine which patients might benefit 
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from this therapy, our data suggest an additional disease modifying therapy that may benefit a 
subset of HPAH patients with NMD negative BMPR2 mutations.  
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CHAPTER IV 
 
GENERATION AND DIFFERENTIATION OF INDUCED PLURIPOTENT STEM 
CELLS FROM HPAH PATIENT FIBROBLASTS 
 
Introduction 
Heritable pulmonary arterial hypertension (HPAH) is a progressive disorder 
characterized by occlusion of small pulmonary arteries leading to increased mean pulmonary 
arterial pressure and right heart failure. Over 200 different mutations have been identified 
throughout the BMPR2 open reading frame in HPAH patients but despite the commonality of 
these mutations disease penetrance is relatively low [45,46,104]. A recent study from Vanderbilt 
suggests that NMD- mutations cause more severe HPAH.  Using mRNA isolated from peripheral 
blood lymphoblasts, they identified 24 NMD- BMPR2 mutations in 54 HPAH patients with 
known BMPR2 mutations. These patients had disease onset and death compared to the NMD+ 
patients that did not produce a mutant BMPR2 transcript [104].  This suggests that NMD- 
BMPR2 mutant products exert dominant inhibitory effects on vascular target cells. 
Evidence of dominant negative effects of an NMD- mutation comes from two 
independent sources. Studies from Nick Morrell’s group show that the NMD- mis-sense BMPR2 
mutation, BMPR2 C118W is mis-folded, retained in the ER and exerts inhibitory effects on BMP 
signaling by sequestrating other BMPR1 receptors in the ER [116]. However, these studies were 
carried out using transient over-expression systems, so the functional consequences of 
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endogenous mutations are largely unknown. Studies from our laboratory have shown that mice 
carrying a heterozygous mutation at the Bmpr2 locus, Bmpr2Ex2/+, which is indistinguishable 
from an NMD- HPAH mutation Family 108, BMPR2EXON2, develop more severe hypoxic PH 
that mice carrying a heterozygous null Bmpr2+/- mutation ([99], Chapter 2). Furthermore, mice 
carrying the Bmpr2Ex2/+ mutation have defects in pulmonary vascular tone with EC dysfunction 
and reduced Smad phosphorylation. The key question therefore is whether endogenously 
expressed NMD- BMPR2 mutant product directly from HPAH patients exert similar dominant 
inhibitory effects.  
HPAH-patient derived cells are rare, difficult to propagate, and usually of end-stage 
disease.  Additionally, it is difficult to get patient cell lines of vascular cells, as this requires a 
lung biopsy.  For these reasons, we decided to generate several iPSC lines from multiple NMD+ 
and NMD- BMPR2 mutant patients in order to study the specific effects of mutation type on 
endothelial cell function.  iPSCs are a new technology that offer a noninvasive way to study 
human genetic diseases.  iPSCs are generated by reprogramming differentiated adult cells to a 
pluripotent, stem cell-like state from which they can be differentiated into a range of different 
cell types. As such, these cells represent an unlimited pool of cells to study cell differentiation, 
disease modeling, and drug therapy [142-144]. Given difficulty in obtaining pulmonary ECs 
from patients with HPAH, this technology provides a unique opportunity to study the biology of 
endogenously expressed BMPR2 mutant products in vascular target cells. There are several 
established methods for reprogramming IPSCs from skin fibroblasts. One of the best 
characterized systems involves the transduction of cultured skin fibroblasts with three ES-cell 
factors, OCT3/4, KLF4, SOX2, using a sequential lentiviral/retroviral over-expression system 
[145]. After 3 weeks, iPSC colonies begin to form, providing a large pool of stem cells that can 
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be used to generate EC.  This method was initially used in these studies to generate control lines .  
After several attempts to use this method to generate iPSCs from HPAH fibroblasts, we changed 
approaches and utilized a different method which added p53 suppression and nontransforming L-
Myc in addition to ES-cell factors OCT3/4, SOX2, KLF4, and LIN28, to generate iPSCs [144].  
Validation of iPSCs includes RT-PCR to check for the expression of pluripotent markers, 
karyotype analysis of each line, and teratoma formation[145].   
Here we describe the generation of several iPSC lines from HPAH fibroblasts containing 
NMD+ and NMD- mutations and begin to develop EC differentiation protocols to study 
endogenous BMPR2 biology in HPAH. This technology will provide a powerful tool to explore 
the biology of BMPR2 mutations in other vascular cell types, and effects of other mutations on 
vascular cell function in other inherited cardiovascular diseases. 
Materials and Methods 
Ethics statement 
The Vanderbilt University Medical Center Institutional Review Boards approved use of 
control of HPAH patient-derived fibroblasts obtained by skin biopsy and participants gave 
informed written consent for use of their fibroblast cultures for study (IRB#9401).  Patient 
fibroblasts were obtained from the Vanderbilt HPAH skin fibroblast repository.  
Patient fibroblast cell culture 
Cells were maintained in complete media, DMEM media (Life Technologies) 
supplemented with 20% fetal bovine serum (FBS)(Sigma), 1% pen/strep (Life Technologies), 
and 1% non-essential amino acids (Sigma).  To passage fibroblasts, complete media was 
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aspirated, cells were rinsed with D-Phosphate Buffered Saline (D-PBS)(Life technologies), and 
detached from 10cm cell culture dish with 0.05% Trypsin-EDTA (Life technologies).  Trypsin 
was neutralized with the addition of complete media, cells were centrifuged, counted and re-
plated as experiment required.         
Generation of human iPSCs from HPAH fibroblasts 
Methods were adapted from [144,146] (Figure 16).  6 X105 patient fibroblasts were 
necessary for transduction. Fibroblasts were trypsinized (see above), and spun in a tabletop 
centrifuge at 200 x g for 5 minutes at room temperature, counted and re-suspended in Neon tube 
(Life technologies) with 115l re-suspension buffer provided in the Neon 100l kit (Life 
technologies).  1g of pCXLE-hOCT3/4-shp53, 1g of pCXLE-hSK, and 1g of pCXLE-hUL 
(plasmids described in [144], Addgene) were added to the fibroblasts in suspension.  Cells were 
electroporated using the Neon transfection system (Life technologies) set to 1,650 volts, 10 ms, 3 
time pulses, per plate.  Cells were then plated in complete media.  Media was changed the next 
day to remove cell debris and then replenished every other day for 7 days.  On day 7, fibroblasts 
were trypsinized and 1 X 105 fibroblasts were plated on 1.8x 106 SNL feeder cells (MMRC, UC 
Davis, CA) per 10cm dish.  24 hours later complete media is changed to hES media: DMEM/F12 
(Life technologies), 20% Knockout serum replacement (Life technologies), 0.5% Glutamax (Life 
technologies), 1% pen/strep (Life technologies), 1% non-essential amino acids (Sigma), rhFGF 
basic (8ng/ml final concentration, Promega), -mercapatoethanol (100M final concentration, 
Sigma).  hES media was replenished daily.  2-4 weeks later, emerging iPS colonies were picked 
individually, plated in 24-well plates coated with stem cell-grade matrigel (BD), per 
manufacturer specified dilution.  5 days later, hES media was replaced with 75% hES, 25% 
mTESR1 (Stemcell technologies).  5 days later, media was transitioned to 50% hES and 50% 
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mTESR1, and so on until iPS colonies were maintained in 100% mTESR1.  Areas of 
differentiation (assessed visually) were manually scraped away from each iPS colony once every 
2-3 days.  Media was replaced daily.        
Immunofluorescence 
Cells were fixed in PBS containing 4% paraformaldehyde (PFA) for 10 minutes at room 
temperature and then permeabilized in 0.1% Saponin for 15 minutes.  Cells were then incubated 
in 10% donkey serum in PBS for 1 hour, and incubated overnight at 4oC with primary antibodies 
at the following dilutions: SSEA3 (1:500 Millipore), SSEA4 (1:500 BD Biosciences), TRA1-81 
(1:500 Millipore), and OCT4 (1:2000 Millipore) diluted in 10% donkey serum in PBS.  
Secondary antibodies conjugated to DyLight 488 (1:200), DyLight 549 (1:400) (Jackson 
ImmunoResearch) were used.   
Alkaline phosphatase assay 
An alkaline phosphatase kit (Sigma) was used to stain iPS colonies, as per manufacturer’s 
protocol. 
Endothelial differentiation 
For these experiments the 2 control iPSC lines BG4 and BG6 (a kind gift from Dr. Kevin 
Ess) were used.  Protocol was adapted from [147,148].  Briefly, iPSCs were grown on SNL 
feeder cells in differentiation media (DM) for 10 days.  VEGFR2+; VE-Cadherin+ cells were 
sorted by a FACS ariaII (BD) and re-cultured onto collagen IV-coated plates without feeder cells 
and addition of 50ng/ml VEGF.   
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FACs sorting 
Cells were detached and pelleted using a centrifuge at 200 x g for 5 minutes.  Cells were           
resuspended, washed in PBS and recentrifuged.  The cell pellet was resuspended in 100l PBS 
containing fluorescently conjugated primary antibodies, CD34-PE (abCam) and VEGFR2-APC 
(BD Pharmigen).  Cells were incubated for 20 minutes on ice protected from light.  Cells were 
then pelleted and washed in ice-cold PBS and re-suspended in 200l of PBS.  FACs analysis was 
performed by the VA FACs CORE.     
RT-PCR validation 
Total RNA from BG4 and BG6 iPScs was prepared using the RNeasy kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions.  Isolated mRNA was then reverse 
transcribed into cDNA on a Thermocycler (Bio-Rad) using SuperScript III (Invitrogen) 
according to the protocol provided by manufacturer.  qRT-PCR was performed with Power 
SYBR Green Master Mix (Applied Biosystems) on an ABI 7900HT fast real-time PCR detection 
system (Applied Biosystems)  
Results 
HPAH fibroblasts with NMD positive and negative BMPR2 mutations 
 We used 4 different HPAH fibroblast cell lines from the Vanderbilt HPAH Tissue 
Repository (Table 4) to generate multiple iPSC lines with the aim to create a protocol to 
differentiate HPAH patient-derived iPSCs into ECs, and to use these ECs to evaluate the NMD 
pathway in patients with different BMPR2 mutations in a physiologically relevant environment.  
Family 14 is a NMD- Cysteine to Tryptophan point mutation occurring at amino acid 118, part  
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Table 4.  HPAH skin fibroblast repository at Vanderbilt (+3 normal controls, +3 HPAH without 
mutation). *Skin fibroblasts used to generate iPSCs. 
 
 
 
 
70 
 
 
 
Figure 16. Method of HPAH fibroblast iPS cell induction.  HPAH fibroblasts are 
electorporated with plasmids driving the expression of p53 shRNA and OCT3/4 (pCXL-
hOCT3/4-shp53), SOX2 and KLF4 (pCXL-HSK), and L-MYC and LIN28 (pCXLE-hUL).  
Fibroblasts are then replated onto SNL feeder cells, DMEM is replaced by hES media, and iPS 
colonies begin to form 2-3 weeks after transduction.     
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of the ligand binding domain of BMPR2.  The C118W mutation has been characterized 
previously using a transient over-expression system, where it was shown that the mutant receptor 
was unable to traffic to the cell surface [116].  F108 is another NMD- mutation, and results in an 
in-frame deletion of BMPR2 EXON2.  We have previously characterized this type of mutation 
using F108 HPAH lymphocytes, a mouse model, Bmpr2Ex/+ (Chapter II and [99]), and in 
primary mouse pulmonary endothelial cells derived from the mouse model (Chapter III).  F150 is 
an NMD+ BMPR2 mutation, a frameshift in the cytoplasmic tail of BMPR2, which is predicted 
to result in a happloinsufficient phenotype.  The final fibroblast line F173 is a predicted NMD- 
missense point mutation, Arginine 491 to Tryptophan, between the kinase domain and 
cytoplasmic tail of BMPR2.  Although predicted to be an NMD- mutation, it is important to note 
that this fibroblast line has not been validated at this time.   
Generation of iPS cells from HPAH fibroblasts 
 In order to generate iPS cell lines from the HPAH fibroblasts, we utilized a method 
reported to have enhanced efficiency of reprogramming with episomal plasmids (Figure 16) 
[145].  This system features two unique characteristics compared to other methods, the addition 
of L-MYC as a reprogramming factor in replacement of the more traditional C-MYC, and the 
suppression of p53 [144].  HPAH fibroblasts were electorporated with plasmids expressing TP53 
shRNA, OCT3/4, L-MYC, SOX2, KLF4, and LIN28 and then reseeded on SNL feeder cells.  
Compared to traditional reprogramming mechanisms with OCT3/4, SOX2, KLF4, c-MYC, LIN28 
and NANOG [142,149], which in our hands yielded less than 5 potential iPS colonies, this 
method resulted in greater than 50 potential iPS colonies.  Potential colonies were expanded 
based on morphology, characterized by large nuclei and minimal cytoplasm and alkaline 
phosphatase staining, which is expressed on the cell membrane of stem cells [150] (Figure 17).  
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Each HPAH fibroblast line produced multiple alkaline positive colonies.  Three were selected 
from each of the original fibroblast lines for further validation; the remaining colonies were 
frozen and stored for future use.  3 F150 and F173 alkaline phosphatase positive colonies were 
expanded and then evaluated for the expression of pluripotent stem cell markers SSEA3 and 
SSEA4 [151], TRA1-81 [152], and OCT4 [153] (Figure 18).  Expression of the pluripotent 
markers varies widely between lines derived from the same HPAH fibroblasts as wells as from 
lines derived from different HPAH fibroblasts, with expression of OCT4 notably reduced in 
almost all lines.  Further validation of the colonies is required before they can be considered iPS 
colonies.  This includes RT-PCR to detect possible integration of episomal plasmids, which 
would result in the invalidation of a line, qRT-PCR to detect the expression of pluripotent 
markers, karyotyping, teratoma formation, and embryoid body formation and differntion. 
Preliminary evaluation of endothelial cell differentiation  
While we were generating iPSCs from HPAH fibroblasts, we evaluated endothelial 
differentiation protocols with control iPSCs BG4 and BG6 with the aim of determining the 
timing of the highest level of expression of endothelial cell markers by using FACs and RT-PCR.  
We began with the simplest endothelial cell differentiation protocol [147,148] (Figure 19.)  We 
first evaluated the expression of endothelial markers CD-34 and VEGFR2 in BG6 cells by FACs 
analysis in cells grown for 10 days in differentiation media compared to normal hES media 
(Figure 20A).  There is a subtle but clear population of cells that express CD34 or VEGFR2 after 
10 days in differentiation media.  We further evaluated the expression of CD34 and VEGFR2 at 
days 0, 2, 4, 6, 8, and 10 in differentiation media.  Cells grown in normal hES media have no 
marked increase in the expression of either CD34 or VEGFR2 (Figure 20B and C).  Conversely, 
there is an increase in cells expressing CD34 and VEGFR2 grown in  
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Figure 17. Preliminary validation of HPAH iPS colonies. Top, potential iPS colonies forming 
2-3 weeks after the 4 HPAH fibroblast lines, F150 (NMD+), F173 (NMD-), F108 (NMD-), and 
F14 (NMD-) were transduced with reprogramming factors.  Each fibroblast line produced greater 
than 10 potential iPS colonies.  Bottom, positive alkaline phosphatase stain of iPS colonies.  
Control is HPAH F150 fibroblasts, and are alkaline phosphatase negative.  Bottom-most panel is 
the expansion of a single F150 colony into multiple colonies.     
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Figure 18.  Expression of pluripotent markers in iPS cell lines.  Three potential iPS colonies 
were expanded and evaluated for pluripotent markers from HPAH F150 and F173.   
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Figure 19.  Endothelial cell differentiation strategy.  Cells are grown in differentiation media 
and the FACs sorted for expression of endothelial markers, replated on collagen-coated plates 
and further differentiated with the addition of VEGF 
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Figure 20.  Expression of CD34-PE and VEGFR2-APC in control iPS line BG6.  A. 
Expression of CD34 and VEGFR2 in undifferentiated cells versus differentiated cells at day 10. 
B. Expression of CD34 in undifferentiated cells at day 0,2,4,6,8, and 10 (day 10 is the blue line). 
C. Expression of VEGFR2 in undifferentiated cells at day 0,2,4,6,8,10 (day 10 is the blue line). 
D. Expression of CD34 in cells undergoing differentiation at day 0,2,4,6,8,10 (day 10 is blue). E. 
Expression of VEGFR2 in cells undergoing differentiation at day0,2,4,6,8,10.   
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differentiation media, but not until day 10 (Figure 20D and 20E, blue line).  These results 
indicate that the highest level of endothelial marker expression is at 10 days in differentiation 
media, and that this would be the optimal time to FACs sort the EC marker expressing cells and 
begin the second part of the differentiation protocol.    
Expression of endothelial cell, smooth muscle cell, and pluripotent markers in BG4 and BG6        
To validate the expression of endothelial cell markers using a second method, as well as 
to evaluate the expression of SMC markers and pluripotent markers, we performed RT-PCR in 
BG4 and BG6 control cells 1, 3, 5, 7, 9, and 11 days after endothelial cell differentiation 
initiation.  We found that BG6 had lower levels of pluripotency markers OCT3, KLF4, NANOG, 
DNMT3B, and SOX2 than BG4 (Figure 21), indicating that those these control cells may be 
harder to maintain as iPS cells, they may demonstrate a greater capacity of differentiation into 
endothelial cells.  This was partially confirmed by evaluation of EC markers (Figure 22).  While 
BG6 cells expressed higher levels of VEGFR2 transcripts, BG4 expressed higher levels of VE-
CADHERIN.  Neither BG6 nor BG4 expressed significant levels of PECAM.  SMC markers were 
more similarly expressed in both control lines.     
Taken together, these results represent a beginning.  Further validation of HPAH iPS 
cells is required before they can be used experimentally.  Additionally, further optimization of 
endothelial differentiation protocols is needed.  However, these findings demonstrate that there is 
variability between iPS lines, and these differences may affect the ability of a cell line to self-
renew and remain pluripotent as well as the lines ability to differentiation into a specific cell 
type.  For example, BG6 expresses EC markers with stimulation and may be easier to push down 
an endothelial lineage than BG4.    
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Figure 21. Evaluation of pluripotent markers in BG4 and BG6 cells undergoing 
differentiation.  BG6 has less expression of OCT3, KLF4, NANOG, DNMT3B, and SOX2 
compared to BG4 except on day 9 of differentiation.   
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Figure 22. Evaluation of markers of endothelial cells and smooth muscle cells in BG4 and 
BG6 cells undergoing differentiation.  BG6 has less expression of endothelial marker VEGFR2 
and reduced expression of endothelial marker VE-CADHERIN compared to BG4.  Neither 
strongly express endothelial marker PECAM. BG6 and BG4 express similar levels of smooth 
muscle cell markers smooth muscle alpha (SMA) and myosin heavy chain (MHC).  
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Discussion 
 The recent advancements in iPS cell generation provides an exciting opportunity to 
evaluate patient-specific responses in a BMPR2 mutation-type and cell-type specific way.  The 
role of BMPR2 signaling in vascular cells isolated from experimental models of PH and from 
patients (often deceased or in end-stage disease) is convoluted and unclear [80,86,95,154].  
iPSCs would provide a limitless source of patient-derived endothelial cells that would otherwise 
be difficult to obtain.  
 Additionally, current treatments for PAH mostly target the vasodilatory response and 
have little effect on vascular remodeling or hemodynamics [36,38-40].  This is compounded in 
HPAH where very few patients respond to current vasodilatory therapies [2].  5 year survival 
rates among these patients are significantly lower than in patients without BMPR2 mutations or 
with other forms of PH [35].  Patient-derived iPSCs could be adapted to a high-throughput 
system that could be used to evaluate patient-specific and mutation-specific responses to drugs, 
aid in drug-discovery, or aid in the identification of new pathways that could be used for more 
targeted for therapies.   
 The differentiation protocol reported here is outdated, and more recent protocols offer 
more detailed and better characterized approaches that result in a larger percentage of cells 
undergoing differentiation [155,156].  That said, there are differences in signaling function and 
protein expression in the vascular endothelium based on where it is localized (proximal or distal) 
and whether it is vascular endothelium or pulmonary vascular endothelium [82,157].  This in part 
leads to the confusion of the role of the endothelium in HPAH.  To date, current differentiation 
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protocols are not detailed enough distinguish between vascular endothelial cell types.  This could 
cause further signaling discrepancies in future studies.    
 In conclusion, this work demonstrates a highly effective system for generating iPS cells 
from patient fibroblasts and provides a preliminary evaluation of HPAH-derived iPS cells, and of 
endothelial differentiation pathways.  Interestingly, BMPR2 signaling has been shown to be a 
necessary component in the differentiation of stem cells and progenitors, usually by promoting 
differentiation [158,159].  It is unclear how the reported HPAH BMPR2 mutations will affect the 
ability of iPS lines to undergo differentiation.           
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CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
 The studies reported in this dissertation were designed to address conflicting clinical data 
that described HPAH patients with NMD+ and NMD- BMPR2 mutations [104,106].  One study 
found a link in a PAH patient cohort between mutant BMPR2 NMD status and severity of 
disease [104], but the other did not find a connection [106].  We used in vivo and in vitro 
techniques to examine this controversy and evaluate the biology of Bmpr2 mutation type in 
experimental models of disease. We identified key physiological and pulmonary vascular 
structure differences between Bmpr2 NMD+ and NMD- mutations.  We continued the 
characterization of the Bmpr2 NMD- mutant using biochemical techniques and identified 
trafficking and signaling defects.  Finally, we began to address the limitations of current HPAH 
patient-derived cells by generating HPAH-patient iPS cell lines expressing BMPR2 NMD+ and 
NMD- mutations.  This chapter will focus on the major conclusions of this dissertation, indicate 
likely avenues of future investigation, and place the key findings of this work in context with the 
current knowledge of HPAH and BMPR2 receptor biology.       
The effect of NMD status in Bmpr2 mutants in vivo and in vitro 
  Chapter II describes studies using 3 models of experimental PH: chronic hypoxia, 
serotonin infusion + chronic hypoxia, and VEGFR2 inhibitor SU5416 + chronic hypoxia 
[96,98,99,110] to evaluate the impact of Bmpr2 mutation type in severity of disease.  We found 
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that NMD- Bmpr2 mutant mice, Bmpr2Ex2/+, have basal signaling defects in phospho-eNOS in 
whole lungs, and in the SU5416 + chronic hypoxia model of PH have increased RVSP and 
number of vascular lesions.   
The reduction in phospho-eNOS we observed in untreated Bmpr2Ex2/+ mice warrants 
further investigation.  An increase in eNOS expression and activity generates the production of 
NO and under normal conditions a vasodilatory response [160].  This leads to the question of do 
these mice have vasocontractility defects basally?  Phospho-eNOS is increased at 1 week, but 
decreased (although not significantly) again at 3 weeks.  The Bmpr2Ex2/+ mice had reduced 
expression of eNOS at 5 weeks in a chronic hypoxia model of PH [99], so it is possible that 
instead of global down-regulation of phospho-eNOS, we are observing mis-regulation of eNOS 
or a feedback loop that regulates eNOS.  For example, it has been shown previously that Bmpr2 
and Caveolin-1 interact [161], and we have shown that the Bmpr2Ex2 mutant product is mis-
localized to the ER.   We hypothesized that sequestration of Bmpr2Ex2 to the ER could alter 
the regulation and localization of other proteins including Caveolin-1  In fact, we have observed 
that Caveolin-1 is mis-localized from the plasma membrane in Bmpr2Ex2/+ PECs (unpublished 
data).  This could be one mechanism for the mis-regulation of eNOS in these cells because eNOS 
directly interacts with Caveolin-1, and is dependent on Caveolin-1 for proper regulation and 
localization [162-164].   
The decrease in phospho-eNOS could contribute to the increased RVSP we observed in 
the SU5416 + chronic hypoxia model.  We have shown previously that Bmpr2Ex2/+ mice have 
reduced eNOS expression in a PH model of 5 weeks of chronic hypoxia [99], and have 
endothelial-cell dependent vasodilatory defects in intra-pulmonary arteries isolated from mice 
84 
 
[99].  PECs isolated from these mice also have decreased Bmp2-stimulated induction of eNOS 
activity compared to WT cells [80].  Therefore, future studies should characterize contractility 
responses in the Bmpr2Ex2/+ mice treated with and without SU5416 and hypoxia.  We should 
also determine if phospho-eNOS is significantly reduced at 5 weeks in the SU5416 + hypoxia 
model - this could indicate that the increased levels of phospho-eNOS at 1 week were transient 
and likely an emergency response of the endothelium to regulate vascular tone.   Myography 
studies in intra-pulmonary arteries from Bmpr2Ex2/+ mice would be useful 1) to determine if the 
mutant mice have basal contractility defects and 2) because it could be used to determine if the 
SU5416 +hypoxia model caused similar contractility defects to those observed in the chronic 
hypoxia model.  Additionally, inhaled NO could be introduced to catheterized mice and changes 
to RVSP monitored.  This approach would provide real-time data to contractility responses in 
mice [165].      
 In addition to eNOS regulation in the Bmpr2Ex2/+ mice and in the SU5416+ hypoxia 
model, we also need to further characterize the vascular lesions we observed in this model.  One 
of the strengths of the SU5416 + hypoxia model is that it recapitulates as best as currently 
possible the vascular lesions that are characteristic of severe cases of PAH.  One of our key 
findings was the increase in number of lesions in the Bmpr2Ex2/+ mice in the SU5416 + hypoxia 
model.  Our next step should be to characterize the cell types that make up the lesions in 
observed in SU5416 + hypoxia treated WT, Bmpr2+/-, and Bmpr2Ex2/+ mice.  In addition to 
vWF and -SMA immunofluorescence to characterize if the lesions are made up of EC and 
SMC, respectively, we should also evaluate the expression of markers for macrophages (CD68), 
T-cells (CD3), and pan-leukocytes (CD45).  Once the cell types making up the lesions have been 
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classified, it will be of interest to determine if the Bmpr2 mutant and WT mice have the same 
types of lesions.      
In Chapter III we further characterized the Bmpr2 NMD- mutant in vitro, providing the 
first evidence of the endogenous expression of the predicted NMD- BMPR2 mutant protein 
product in two HPAH-relevant cell lines: lymphocytes derived from HPAH patients [47,122-
124], and mouse primary pulmonary arterial endothelial cells [51,78,81,91,97,100,166].  We 
show that the mutant has trafficking and signaling defects that can be partially restored with 
chemical chaperone 4-PBA treatment.  
The next step in this project would be to characterize the effect of 4-PBA treatment on 
WT, Bmpr2+/-, and Bmpr2Ex2/+ mice in the SU5416 + hypoxia model of PH.  4-PBA has 
already been used in vivo in other experimental models of disease [128,132,133,167,168].  For 
our studies, we would evaluate if in vivo treatment of 4-PBA, and if the restoration of the mutant 
receptor to the cell surface, has any ameliorating effect on susceptibility to PH.  If there is an 
effect in susceptibility, measured by RVSP, it may be challenging, but necessary to show that 
this is definitively caused by restoration of receptor trafficking to the cell surface.  4-PBA, in 
addition to being a chemical chaperone, is also an HDAC inhibitor, which is why it is important 
to validate that any changes to susceptibility in vivo were due to its function as a chemical 
chaperone and not an HDAC (which can be evaluated by histone acetylation) [169,170].  Dosage 
regimes and timing would need to be optimized. Phospho-Smad1/5/8 could be used as an 
assessment of the restoration of receptor signaling function with chemical chaperone treatment in 
vivo, however based on our studies in chapter 2, this would need to be assessed after 1 week of 
SU5416+Hypoxia, which was the only time-point where phospho-Smad1/5/8 was significantly 
reduced.          
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In addition to in vivo studies of chemical chaperone treatment on mutant receptor 
function, it would also be of interest to identify and validate in vitro interacting partners of the 
Bmpr2Ex2 mutant product.  It has been shown that certain NMD- mutants may lead to 
increased severity of disease by acting as dominant-negative proteins [116]; this was, however, 
using FLAG-tagged proteins in an artificial expression system.  If possible, it would be more 
impactful and biologically relevant to identify endogenous protein interactions with the mutant 
Bmpr2 receptor.  Unfortunately, these studies are limited because of the quality of antibodies.  A 
likely interaction of the mutant receptor would be with the Type I Bmp receptors.  However, 
these studies are hampered by the lack of a suitable Type I receptor antibody to use in 
immunoprecipitation-type studies.  Still, there are other protein interactions that could be 
assessed.  We have already observed the mislocalization of Caveolin-1 in these cells.  This 
mislocalization of Caveolin-1 could be due to dominant negative effects of the Bmpr2Ex2 
receptor.  Bmpr2 can also form homodimers, which if this occurred in the ER with the mutant 
receptor, would restrict the availability of the WT receptor at the cell surface-altering Bmpr 
receptor complex formation and modulating downstream signaling function[60,61]. 
Another future direction of research is the characterization of protein turnover in the 
Bmpr2Ex2 receptor, specifically caused by activation of the ER associated degradation 
pathway (reviewed in [171-173]).  Preliminary data from ciECs show that when cells are treated 
with BMP2, the expression of the WT receptor is decreased, indicating that the receptor is likely 
internalized and degraded.  In contrast, in Bmpr2Ex2+/- ciECs stimulated with BMP2, the mutant 
Ex2 receptor is maintained at high levels while the WT receptor is decreased.  The mutant 
Bmpr2 may have decreased turnover due to the Ex2 mutation.  Exon2 contains 3 cysteine 
residues important for disulfide bond formation and proper protein folding in the ER [135].  The 
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missing cysteine residues led us to hypothesize that the Bmpr2 mutant product was likely 
unstable, misfolded, and mislocalized.  In addition to the cysteine residues, Exon2 also contains 
an asparagine residue in a potential N-linked glycosylation motif [174].  The identification of the 
missing asparagine residue as crucial for proper processing of the Bmpr2 protein in the ER 
would be a novel finding.   Because of the Ex2 mutation, it is possible that the missing 
asparagine residue prevents proper glycosylation in the ER, and possibly prevents proper 
recognition by the ER quality control machinery [126,136].  If the mutant product is not 
recognized, or not efficiently recognized by the ERAD machinery, it would result in the buildup 
of Bmpr2 mutant protein in the ER [175].  That said, there is likely some turnover of the mutant 
protein because it is not expressed in massive amounts.  To assess this properly, rate of protein 
synthesis should also be determined, but this represents a novel area of research that would link 
to oxidative stress generation in the ER, ER stress, and UPR responses.  Initial assessment did 
not detect activation of ER stress, but more stringent characterization could yield different 
results.              
Generation and preliminary validation of HPAH patient-derived IPS cells 
In Chapter IV, we begin to address the limitations of current HPAH patient-derived cells.  
Currently available HPAH patient cells are usually from end-stage disease, are likely altered 
because of the various patient treatment regimes, and are not the cell type of interest.  For 
example, they are patient fibroblasts or lymphocytes instead of pulmonary vascular endothelial 
cells or smooth muscle cells. We attempt to address the lack of endothelial or smooth muscle 
HPAH patient cells in chapter IV by generating and beginning validation of HPAH-patient iPS 
cell lines expressing BMPR2 NMD+ and NMD- mutations.   
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To be able to use the generated iPS cells experimentally, a number of validation assays 
must first be completed.  To do this, we need to first use PCR to confirm that the plasmids used 
to generate the cell lines did not genomically integrate into the iPS lines.  While iPS lines with 
integrated plasmids can be used experimentally, they increase the risk of tumor formation in 
mice and absolutely could not be reintroduced into patients because the expression of 
reprogramming factors used to derive the iPS cells would be uncontrolled, driven by a 
constitutively active promoter [144].  Additionally, integration of plasmids driving the 
expression of reprogramming factors will likely affect the ability of an iPSC line to undergo 
differentiation.  We would then need to perform RT-PCR analysis of pluripotent markers using 
human embryonic stem cells as a positive control to confirm expression levels were similar.  
Additionally, DNA methylation status of the NANOG promoter region in the patient fibroblasts, 
iPS lines, and human stem cell lines would be needed to show that the iPS cells were more like 
stem cells and less like the patient fibroblasts from which they were derived.  Next, the iPS lines 
would need to be karyotyped to assure there are no gross chromosomal abnormalities from the 
change from fibroblasts to iPS cells.  And finally, the iPS cell lines would need to be evaluated 
for the formation of all three germ layers, assessed either by embryoid body formation in vitro or 
teratoma formation in mice [142,144] 
Once the iPSC are validated, the ultimate goal is to generate highly efficient and directed 
differentiation protocols to pulmonary vascular cell types.  At the time, we were limited by the 
number of established protocols to generate endothelial cells [147,148].  Therefore, we began our 
differentiation studies with the most basic protocol with the intention of advancing from there.  
Because of time and financial constraints, further optimization never occurred.  Now, however, 
there are more practical and efficient vascular endothelial differentiation protocols [155,156].  
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One important caveat is that although there are protocols available for vascular endothelial cells, 
vascular endothelial cells are not the same cell type as pulmonary vascular endothelial cells, or 
even pulmonary microvascular endothelial cells [82].  We and others have already shown that 
Bmpr2-mediated signaling effects are cell-type specific [51,80,176], so it will be important to 
establish exactly what type of endothelial cell you are differentiating your HPAH-derived iPSCs.  
Once efficient endothelial cell differentiation has been achieved, other vascular cell types should 
be investigated, specifically pulmonary vascular smooth muscle cells.   
The generation of HPAH patient-derived iPSCs began as a side project.  We quickly 
realized that the generation of iPSCs was in fact a main project with both demands on time and 
expense.  Because of this, we froze our iPSCs once they were generated, but before they were 
completely validated.  Instead we turned our attention to an alternate source of HPAH patient 
cells- endothelial progenitor cells (EPCs), reviewed in [177-180].  These cells can be easily 
isolated from patient blood, and exhibit characteristic expression patterns and signaling function 
to endothelial cells.  In fact, late outgrowth EPCs display most characteristics of endothelial 
cells, so may be the more biologically relevant, easily accessible EPC population for our studies 
[179].  Studies are underway in our lab to determine signaling capabilities in these cells, and to 
evaluate the effects of NMD+ and NMD- BMPR2 mutations on those pathways.      
In conclusion, the studies reported in this dissertation examine the role of BMPR2 
mutation type in HPAH.  Over 70% of HPAH patients have a mutation in BMPR2, and with over 
200 different mutations identified throughout the reading frame of the gene [45,47], it is 
challenging to determine the definitive role of BMPR2 mutation in disease pathogenesis.  In fact, 
it is likely that mutations located in different regions of the gene result in different disease 
phenotypes.  A mutation that is expressed (NMD-) could behave as a dominant negative, with 
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evidence supporting this in over-expression systems [79,116], or mutations could be recognized 
by RNA surveillance machinery and degraded (NMD+) and result in a haploinsufficient effect 
[125].  It is also likely that mutants of the NMD- type do not contribute the same way to disease.  
For example a cysteine point mutation in the ligand binding domain is mis-trafficked, leading to 
signaling defects [103,116].  Conversely, a mutation in the cytoplasmic tail domain of Bmpr2 
would likely result in disrupting protein interactions but not alter the Smad pathway [103,181].  
Taken together, the studies reported in this dissertation provide key information on biological 
principles underlying clinical data, basic Bmpr2 receptor and mutant receptor biology, offer 
proof of principle for a potential therapeutic for certain types of Bmpr2 mutation, and begin to 
generate HPAH patient iPS cell lines to address the lack of available HPAH cell lines that are 
biologically relevant to disease pathogenesis. 
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